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ABSTRACT 
    Treatment of rheumatoid arthritis (RA) should be targeted at remission. The best strategy to 
achieve this goal is tight disease control and intensive monitoring of disease activity. 
   The purpose of the present study was to compare different definitions of remission in RA, to 
study sustainability of remission, and to evaluate DAS28 as an index in the assessment of 
remission and disease activity in RA. Furthermore, we set out to develop a new, simple disease 
activity index for RA: the Mean Overall Index of disease activity for RA (MOI-RA). 
   Two patient populations were analyzed: 1) the clinical cohort included all adult RA patients 
who were diagnosed at Jyväskylä Central Hospital in 1997 and 1998 (237 patients), and 2) the 
FIN-RACo trial patients (195 patients).  
   At five years, 17% of the clinical cohort patients met the ACR remission criteria, 37% met the 
clinical remission criteria (no tender or swollen joints and normal erythrocyte sedimentation rate 
[ESR]), and 55% met the criteria for radiographic remission (no worsening of erosions and no 
new erosions from baseline to five years). Only 12% of the patients met all three sets of 
remission criteria. In patients with DAS28 remission (DAS28<2.6), 23% had tender joints, 9% 
had swollen joints, and 6% had both tender and swollen joints. 
   In the FIN-RACo trial, 68% of the patients who received combination therapy with traditional 
DMARDs and 41% of the monotherapy patients were in DAS28 remission at 2 years, and 
remission was sustained in 51% and 16% of the patients, respectively.  
   ESR had the greatest effect on DAS28 in the FIN-RACo population, followed by tender joint 
count (TJC), global health, and swollen joint count (SJC).  
    MOI-RA is the mean of standardized values of TJC and SJC, self reported physical function 
on the Health Assessment Questionnaire (HAQ), patient’s and physician’s assessments of 
global health and patient’s assessment of pain, and ESR. All seven components are 
standardized, and the mean of standardized values is calculated. The range of MOI-RA is 0-
100, higher values indicating poorer outcomes. 
   The reproducibility of MOI-RA with different joint counts was 0.97. Correlation between MOI-
RA28 and DAS28 was 0.90. A simulation in which 15% of the component values of MOI-RA 
were randomly omitted indicated an intraclass correlation coefficient of 0.98 between 
incomplete and complete data. 
   The rate of remission in RA depends on the criteria used. Sustained remission, which is more 
often achieved by patients receiving combination therapy, protects RA patients against 
radiographic joint damage. A substantial proportion of patients below the DAS28 cutoff point for 
remission had tender and/or swollen joints.  
  The new disease activity index for RA (MOI-RA) proved to be a simple and feasible index for 
assessment of disease activity and treatment response.  
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2.  ABBREVIATIONS 
 
ACR American College of Rheumatology  
ACR-N Continuous index based the percentage change in the ACR core 
set of disease activity measures 
Anti-CCP Anti-cyclic citrullinated peptide antibodies 
ARA American Rheumatism Association 
AUC Area under curve    
CDAI Clinical Disease Activity Index 
CI Confidence Interval 
CRP C-reactive protein 
DAS Disease Activity Score 
DAS28 Disease Activity Score with 28 joints 
DMARD Disease modifying antirheumatic drug 
EGA Evaluator’s global assessment of disease activity 
ES Effect size 
ESR Erythrocyte Sedimentation Rate 
EULAR European League against Rheumatism 
FIN-RACo Finnish Rheumatoid Arthritis Combination Therapy Trial 
FDA Food and Drug Administration 
GEE Generalized estimating equations    
GH Global health 
GL Physician’s global assessments 
GM-CSF Granulocyte-macrophage colony-stimulating factor  
HAQ Stanford Health Assessment Questionnaire 
HAQ-DI HAQ Disability Index  
HR Hazard ratio 
HLA Human leukocyte antigen 
IP Interphalangeal (joint) 
ICC Intraclass correlation 
JSN Joint space narrowing 
IQR Interquartile range 
MCP Metacarpophalangeal (joint) 
MDA Minimal Disease Activity for Rheumatoid Arthritis  
MOI-RA Mean Overall Disease Activity Index for Rheumatoid Arthritis 
MTP Metatarsophalangeal (joint) 
nACR Number of core set measures improved by ≥ 20% 
OR Odds ratio 
PGA Patient global assessment of disease activity 
PRO Patient Reported Outcome 
PIP Proximal interphalangeal joint 
RCT Randomized Controlled Trial 
RA Rheumatoid arthritis 
RADAI Rheumatoid Arthritis Disease Activity Index  
  
RADAR Rapid Assessment of Disease Activity in Rheumatology 
RAPID  Routine Assessment of Patient Index Data  
RF Rheumatoid factor 
SE Shared epitope  
SDAI Simplified Disease Activity Index 
SJC Swollen joint count 
SRM Standardized response mean  
TJC Tender joint count 
VAS Visual analog scale  
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3.  INTRODUCTION 
The current treatment approach for patients with rheumatoid 
arthritis (RA) involves early initiation of aggressive therapy with disease 
modifying drugs (DMARDs) and biologic agents (Möttönen et al., 2002; 
Goekoop-Ruiterman et al., 2005; Sokka et al., 2005). The goal of treatment is 
remission (Emery & Salmon, 1995; Möttönen et al., 1999). Measurement of 
disease activity is useful for guiding therapy (Grigor et al., 2004; Fransen et al., 
2005; Goekoop-Ruiterman et al., 2005) and a single standardized disease 
activity index would be most desirable for scientific purposes. Nevertheless, 
several different definitions of remission and various disease activity indices are 
currently in use. 
The ACR (American College of Rheumatology - formerly ARA, 
American Rheumatism Association) remission criteria are strict and include 
nonspecific symptoms such as fatigue (Pinals et al., 1981). More recently, 
remissions based on the Disease Activity Score (DAS) and DAS28 have been 
described (Prevoo et al., 1996; van Riel & van Gestel, 2000).  However, 
patients who meet DAS28 remission with values of < 2.6 may still have tender 
and/or swollen joints (Aletaha et al., 2005b). The ACR remission criteria are 
more rigorous than those of DAS28<2.6. Newer tools for evaluation of RA 
activity include the Simplified Disease Activity Index (SDAI), and Clinical 
Disease Activity Index (CDAI). Remission cut off points for these new composite 
indices have also been defined (Aletaha & Smolen, 2005).  The use of the 
stringent ACR remission criteria has been replaced with DAS28 remission 
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criteria that provide higher remission rates.  ACR remission criteria have not 
been used for RA in randomized controlled trials (RCTs) to test the efficacy of 
biological agents (Mäkinen et al., 2006) 
Regular assessments of disease activity can successfully be used 
in the clinic for guiding treatment (Grigor et al., 2004; Fransen et al., 2005; 
Goekoop-Ruiterman et al., 2005; Verstappen et al., 2007). Indices are also 
needed in RCTs to prove the efficacy of a new therapy. Indices used in RCTs to 
document the efficacy of a treatment of RA include the American College of 
Rheumatology (ACR) improvement criteria (Felson et al., 1995) (Table 1), later 
known as the ACR20 response and then succeeded by higher thresholds for 
improvement, the ACR50 and ACR70 (Felson et al., 1998).  The DAS (van der 
Heijde et al., 1990; van der Heijde et al., 1993) and its modified version 
including 28 joints (DAS28)(Prevoo et al., 1995), provide  European League 
Against Rheumatism (EULAR) response criteria. The ACR and EULAR 
response criteria are the current standards for monitoring treatment response in 
RA clinical trials (van Gestel et al., 1996). Minimal disease activity (MDA) of RA 
can be assessed using definitions that are based on either  DAS28 or the ACR 
core set criteria (Wells et al., 2005).   
Recently, additional composite indices have been presented: SDAI 
(Smolen et al., 2003) and CDAI (Aletaha et al., 2005a). Both are based on a 
simple sum of the values of outcome parameters: tender (TJC) and swollen 
(SJC) joint count based on 28 joints, patient’s global assessment of disease 
activity [visual analog scale (VAS) 0-10 cm], physician’s global assessment of 
  
19 
disease activity (VAS 0-10 cm), and C-reactive protein (CRP is not included in 
CDAI).  ACR-N (Bathon et al., 2000), the Hybrid Measure of ACR (Committee, 
2007) and other continuous indices  which are based on ACR core data set 
measures, assess percentage change in disease activity instead of current 
disease activity.  Indices based only on patient reported outcomes such as the 
patient activity score (Wolfe et al., 2003) also discriminate effectively between 
active and control treatments in clinical trials (Pincus et al., 2003; Pincus et al., 
2005a; Pincus et al., 2006). 
The present study was focused on measurement of disease activity 
and remission in early RA. The purpose of the study was to compare different 
definitions of remission in RA, to study sustainability of remission, and to 
evaluate DAS28 as an index for assessing disease activity in RA. In addition, 
we set out to develop a novel simple and feasible disease activity index for RA 
including various dimensions of disease activity. 
 
4. REVIEW OF THE LITERATURE 
4.1. Rheumatoid arthritis (RA) 
RA is a heterogeneous autoimmune disease with variable outcome.  
The primary target of inflammation in RA is the synovium. However, RA is a 
systemic disease, sometimes with features such as fatigue (Pollard et al., 
2006), low-grade fever (Pinals, 1994), anemia (Wolfe & Michaud, 2006), or/and 
elevations of acute phase reactants (Yildirim et al., 2004).  
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The currently accepted classification criteria for RA are based on 
the 1987 American College of Rheumatology criteria. These criteria comprise 
seven components, four of which must be fulfilled (Arnett et al., 1988). Early 
initiation of treatment is needed to reduce structural damage in RA (Möttönen et 
al., 2002). The classification criteria for RA were developed in patients with 
established disease, not early RA. Therefore, the use of these criteria for 
diagnostic purposes is not reasonable in clinical practice, although they are 
widely used in RA studies.  
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Table 1. 1987 Criteria for the Classification of Rheumatoid Arthritis (Arnett et al., 
1988) 
 
Criterion Definition 
1. Morning stiffness Morning stiffness in and around joints, lasting 
at least 1 hour before maximal improvement  
2. Arthritis of 3  or more joint 
areas 
At least 3 joint areas simultaneously have 
had soft tissue swelling or fluid (not bony 
overgrowth alone) observed by physician. 
The 14 possible areas are right or left PIP, 
MCP, wrist, elbow, knee, ankle, and MTP 
joints 
3. Arthritis of hand joints At least 1 area swollen (as defined above) in 
a wrist, MCP, or PIP joint 
4. Symmetric arthritis Simultaneous involvement of the same joint 
areas (as defined in 2) on both sides of the 
body (bilateral involvement of PIPs, MCPs, or 
MTPs is acceptable without absolute 
symmetry)  
5. Rheumatoid nodules Subcutaneous nodules over bony 
prominences, or extensor surfaces, or in 
juxtaarticular regions, observed by a 
physician   
6. Serum rheumatoid factor Demonstration of abnormal amounts of 
serum rheumatoid factor by any method for 
which the result have been positive in < 5% 
of normal control subjects 
7. Radiographic changes Radiographic changes typical of rheumatoid 
arthritis on posteroanterior hand and wrist 
radiographs, which must include erosions or 
unequivocal bony decalcification localized in 
or most marked adjacent to the involved 
joints (osteoarthritis changes alone do not 
qualify)  
 
 
 
 
For classification purposes, a patient shall be said to have RA if he/she has 
satisfied at least four of these seven criteria. Criteria 1 through 4 must have 
been present for at least six weeks.  
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                  The prevalence of RA varies between countries and areas of the 
world. The median prevalence estimate for the total population in south 
European countries is 0.3%, for north European countries 0.5% and for 
developing countries 0.4% (Alamanos et al., 2006). A retrospective study from 
USA showed a prevalence of 1% (Gabriel et al., 1999). In Finland 0.8% of the 
adult population has RA (Hakala et al., 1993; Aho et al., 1998).  The annual 
incidence of RA lies between 26 and 46/100 000 (Symmons et al., 1994; Uhlig 
et al., 1998; Riise et al., 2000; Soderlin et al., 2002) in most adult populations.  
The annual incidence of RA in Finland was studied from a nationwide sickness 
insurance register in a district with a population base of about 1.8 million adults; 
the incidence of RA was 31.7/100 000 in 1995 (Kaipiainen-Seppänen et al., 
2001). The same register was used in  2000, and the incidence of RA was 
29.1/100 000 (Kaipiainen-Seppänen & Kautiainen, 2006). A declining trend has 
been noted in the incidence of rheumatoid factor (RF) positive RA between 
1980 and 2000 (Kaipiainen-Seppänen & Kautiainen, 2006). The annual 
incidence of RA in Kuopio, Finland was 36/100 000 in 2000 (Savolainen et al., 
2003). 
The etiology of RA is largely unknown.  According to epidemiologic 
studies both genetic and environmental factors contribute to the onset of RA. 
RA has a heredity of approximately 60% (MacGregor et al., 2000). The genetic 
and environmental risk factors for RA may be different in different disease 
subtypes [RF positive/negative, anti-cyclic citrullinated peptide antibody (anti-
CCP)  positive/negative] (Klareskog et al., 2006a). The most impressive 
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evidence of an environmental factor exists for smoking (Heliövaara et al., 1993). 
Klareskog et. al. (Klareskog et al., 2006b) have presented a hypothesis for the 
etiology of anti-CCP positive RA, in which an environmental agent (smoking) 
induces citrullination of lung proteins. Adjuvants in the smoke also stimulate the 
innate immune system, and help to induce immunity to citrullinated proteins 
preferentially in individuals carrying the HLA-DR shared epitope (SE) genes.   
The development of arthritis in RA patients is preceded by the 
occurrence of autoantibodies years before disease onset (Aho et al., 1985; 
Klareskog et al., 2006a). Practically every immune cell type and inflammatory 
mediator has been implicated in the disease process over the course of time 
(Firestein, 2005). Hypotheses on B-cells are currently of interest because of B-
cell targeted therapies (Edwards et al., 2004). T-cell directed treatment 
approaches have also proved to be effective (Kremer et al., 2003). Cytokines 
such as tumor necrosis factor alpha (TNF-alpha) and interleukin-1 (IL-1), IL-6, 
IL-18 and granulocyte-macrophage colony-stimulating factor (GM-CSF) play a 
crucial role in the pathogenesis of RA (Feldmann et al., 1996). Chronic synovitis 
is characterized by a complex interplay between multiple cell types and 
inflammatory mediators.   
The most dominant feature of RA is arthritis. The most commonly 
affected joints are the small joints of hands and feet, with a symmetric pattern of 
inflammation. The clinical features reflecting systemic involvement in RA include 
fever, malaise, fatigue and weight loss. RA patients may also have extra-
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articular manifestations affecting the vascular system, lungs, kidneys, nervous 
system, eyes and skin. 
The clinical course of RA varies from self limiting or episodic to 
prolonged and progressive chronic arthritis. The latter may result in extensive 
joint destruction (Ollier et al., 2001).  Today the clinical status of RA patients 
who have been actively treated is improved compared to previous decades, 
according to disease activity (Bergstrom et al., 1999; Pincus et al., 2005b), 
function and structural outcomes (Sokka et al., 2000b; Sokka et al., 2004a; 
Heiberg et al., 2005; Pincus et al., 2005b; Sokka et al., 2007a), work disability 
(Puolakka et al., 2005) and mortality (Krause et al., 2000; Choi et al., 2002). 
 
4.2. Assessment of disease activity in RA 
A single ‘gold standard’ measure does not exist for the assessment 
of RA disease activity  such as blood pressure or serum cholesterol, to be used 
in clinical trials, clinical research and clinical care (Pincus & Sokka, 2005). 
Therefore, a pooled index of several individual measures is required (Smythe et 
al., 1977). 
The ACR preliminary core set of disease activity was published in 
1993. These measures consist of tender joint count, swollen joint count, 
patient’s assessment of pain, patient’s and physician`s assessments of disease 
activity, self reported physical function, and laboratory evaluation of an acute-
phase reactant. For studies lasting one year or longer, radiographs are 
recommended (Felson et al., 1993). Measures were selected based on their 
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sensitivity to change, their lack of redundancy, their content validity (whether 
they sampled multiple domains of RA activity), and whether they predicted 
important outcomes in RA, including disability, radiographic damage and death. 
The ACR criteria for remission (Pinals et al., 1981), the ACR improvement 
criteria (Felson et al., 1995), and different continuous disease activity indices 
include these measures in various combinations. 
  
4.2.1. Single measures of disease activity in RA 
4.2.1.1. Joint counts 
The most important phenomenon in RA is inflammation of joints; 
consequently measurement of tender and swollen joint counts is an essential 
part of disease activity measurement in RA.  Formal joint counts used in most 
studies have ranged from 28 to 68 joints. 
Joint counts are the principal components of the ACR remission 
criteria (Pinals et al., 1981) and the ACR core set for clinical trials (Felson et al., 
1995). Tender and swollen joint counts are also included in the DAS (van der 
Heijde et al., 1990; van der Heijde et al., 1993) and in a modified version of the 
DAS including 28 joints (DAS28) (Prevoo et al., 1995), as well as  in newer, 
more simple indices derived from them: SDAI (Smolen et al., 2003) and CDAI 
(Aletaha et al., 2005a).  Joint counts should be included in the clinical 
examination of every RA patient at each visit (Scott et al., 2003). However, most 
visits to a rheumatologist do not include a formal joint count (Pincus & 
Segurado, 2006) . 
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Abnormalities assessed in joints include swelling, tenderness, pain 
on motion, limited motion, and deformity. Effusion is a characteristic feature in 
swollen joints, not bony enlargement or deformity. Joint tenderness is defined 
as pain induced by pressure or motion on joint examination. Pressure 
tenderness is often difficult or impossible to assess in shoulder and hip joints. 
Thus the tenderness of these joints is assessed by pain in motion  (Sokka & 
Pincus, 2005).  
The most frequently used joint counts are presented in Table 2. 
The joint counts including 66/68 joints have been replaced with more limited 
joint counts in DAS28, SDAI and CDAI. In the original DAS the tender joint 
count is substituted by the Ritchie Articular Index (Ritchie et al., 1968), which 
constitutes 52 joints (Table 2). Joints are assessed using the following grading: 
0 = non-tender, 1 = tender, 2 = tender with wincing, and 3 = tender with wincing 
and withdrawal. The range of the Ritchie Index is 0 to 78. The swollen joint 
count of the original DAS ranges from 0 to 44 (van der Heijde et al., 1990; van 
der Heijde et al., 1993) (Table 2).   
Joint counts may also be a part of self administered questionnaires 
assessing disease activity in RA. The Rapid Assessment of Disease Activity in 
Rheumatology (RADAR) index includes the patient self reported joint count as a 
component (Mason et al., 1992).  The Rheumatoid Arthritis Disease Activity 
Index (RADAI) is a further development of RADAR (Stucki et al., 1995). In the 
RADAI-index, the patients rate their joint pain as 0= none, 1= mild, 2= 
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moderate, 3=severe in the right and left shoulders, elbows, wrists, fingers, hips, 
knees, ankles and toes. 
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Table 2. Joints included in different joint counts. 
 
Joints 
28 joints 
(Fuchs et 
al., 
1989a) 
42 joints 
(Sokka & 
Pincus, 
2003a) 
44 joints 
(van der 
Heijde 
et al., 
2006) 
66/68 
joints  
Ritchie 
Index 
(Ritchie 
et al., 
1968) 
Temporomandibular    + + 
Sternoclavicular   + + + 
Acromioclavicular   + + + 
Shoulder + + + + + 
Elbow + + + + + 
Wrist + + + + + 
Metacarpophalangeal (1-5) + + + + + 
Proximal interphalangeal (1-5) + + + +  
Distal interphalangeal (2-5)    +  
Hip (assessed for tenderness only)  +  + + 
Knee + + + + + 
Ankle  + + + + 
Talocalcaneal     + 
Tarsus    + + 
Metatarsophalangeal (1-5)  + + + + 
Proximal interphalangeal (1-5)    +  
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4.2.1.2. Assessment of pain in RA 
Pain is a common symptom in the general population and its 
prevalence increases with advancing age. Pain is the major reason for RA 
patients to seek medical care and is the priority area for improvement of health 
for RA patients (Heiberg & Kvien, 2002). However, pain is not generally 
recorded by health professionals. The experience of pain is subjective and 
difficult to measure (Sokka, 2003). Extensive self-report research 
questionnaires have been developed to measure the quantitative and qualitative 
properties of pain (Huskisson, 1974). These questionnaires may be difficult and 
time-consuming to use in clinical settings.  
A visual analog pain scale was initially used in psychology in the 
early 1900s (Sokka, 2005). This approach was adopted by rheumatologists in 
the 1970s, with the emphasis that ‘severity of pain is only known to the sufferer’ 
(Huskisson, 1974). The standard visual analog scale (VAS) is a 10 cm scale 
with a border at each end. The left border represents ‘no pain’ and the severity 
of pain increases to the right; accordingly the right border is characterized as 
‘pain as severe as it could be’.  
Widespread musculoskeletal pain was reported by a quarter of 
1002 community dwelling elderly women in the US (Leveille et al., 2001). Pain 
was found to be the leading reason for a general practitioner visit in Finland. In 
the 15-74 year old Finnish population, 35.1% suffer from chronic pain, and the 
prevalence of pain increases with age (Mäntyselkä et al., 2003). 
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Pain is a component of the ACR response criteria (Felson et al., 
1995), and absence of joint pain is included in the ACR remission criteria for RA 
(Pinals et al., 1981).  On a 100 mm VAS scale < 10 mm has been interpreted as 
no pain (Sokka & Pincus, 2003b). The Minimal Disease Activity for Rheumatoid 
Arthritis (MDA) core set definition for pain cut-off is ≤ 20 mm on a VAS (Wells et 
al., 2005). In an elderly Finnish population the mean pain VAS was 20 
mm(Krishnan et al., 2005).  
 
4.2.1.3. Global assessments of severity in RA 
All disease activity indices include a patient self-report global 
measure; this is defined as ‘global health’ (GH) in the DAS and the DAS28 
indices, and as ‘patient global assessment of disease activity’ (PGA) in the 
SDAI and the CDAI indices. Global health includes a broader spectrum of 
aspects of health, and not all are directly related to RA. Smedstad et al. 
(Smedstad et al., 1997) found strong correlations between GH and pain, 
depression, disability and tender joints, while ESR, CRP, and X-ray 
abnormalities correlated weakly with GH. The physician’s impression of disease 
activity is supposed to influence clinical decisions with regard to intensifying or 
reducing treatment of RA. Patients often score their disease activity at a higher 
level than physicians do (Yazici et al., 2001; Nicolau et al., 2004). Physicians 
seem to weight findings which are regarded as more objective, like abnormal 
laboratory tests or swollen joint counts. Both GH and physician’s global 
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assessments (GL) are part of the ACR core set of improvement for RA and 
SDAI, while GL is not included in DAS and DAS28.  
 
4.2.1.4. Assessment of function in RA: The Health Assessment 
Questionnaire (HAQ) 
Patient-reported outcomes (PROs) provide knowledge about 
patient’s health, functional status, symptoms, treatment preferences, 
satisfaction and quality of life from their own personal perspective. The Health 
Assessment Questionnaire (HAQ) introduced in 1980 is among the first PRO 
instruments that was initially designed to present a model of patient-oriented 
outcome assessment (Fries et al., 1980; Bruce & Fries, 2005).  
HAQ consists of the HAQ Disability Index (HAQ-DI), pain VAS, and 
patient global VAS. HAQ-DI includes questions about fine movements of the 
upper extremity, locomotor activities of the lower extremity, and activities that 
involve both the upper and lower extremities. There are 20 questions in eight 
categories of functioning: dressing, arising, eating, walking, hygiene, reaching, 
gripping, and performing tasks. Patient’s responses describing abilities over the 
past week are scored as follows: 0= without any difficulty, 1= with some 
difficulty, 2= with much difficulty, and 3= unable to do it. The highest component 
in each category determines the score of that category, unless aids or devices 
are required. Dependence on equipment or physical assistance increases a 
lower score to the level of 2. A complementary scoring method ignores the 
score for aids and devices and represents residual disability after compensatory 
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efforts. The HAQ-DI score ranges from 0 to 3: scores of 0 to 1 are generally 
considered to represent mild to moderate disability, from 1 to 2 moderate to 
severe disability, and from 2 to 3 severe to very severe disability (Bruce & Fries, 
2003) . The HAQ has been translated into numerous languages, has been used 
extensively in RA studies, and is a component of ACR response criteria (Felson 
et al., 1995). HAQ has been assessed in a random sample of 1530 elderly 
Finnish population, producing a mean value of 0.25; at least some disability was 
seen in 32% of responders (Krishnan et al., 2004).  
The modified HAQ, derived from the original HAQ, was published 
1983 (Pincus et al., 1983).  The number of questions was limited to eight 
instead of 20, and one question in each category of HAQ was included. The 
sum of scores for the questions is divided by eight to achieve a score of 0-3.  
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HEALTH ASSESSMENT QUESTIONNAIRE  (HAQ)     
ID _____________________________ Date of Birth    Today’s Date   
This questionnaire includes information not available from blood tests, X-rays, or any source other than you.  Please try 
to answer each question, even if you do not think it is related to you at this time.  There are no right or wrong answers.  
Please answer exactly as you think or feel.  Thank you. 
 
1. We are interested in learning how your illness affects your ability to function in daily life. Please  
check (√) the one best answer which best describes your usual abilities OVER THE PAST WEEK: 
DRESSING & GROOMING 
Without ANY 
Difficulty(0) 
With SOME 
Difficulty(1) 
With MUCH 
Difficulty(2) 
UNABLE  To 
Do(3) 
Are you able to:     
(X) Dress yourself, including tying shoelaces and                                                 
  doing buttons? ______ ______ ______ ______ 
   - Shampoo your hair? ______ ______ ______ ______ 
ARISING      
Are you able to:     
   - Stand up from a straight chair? ______ ______ ______ ______ 
   (X) Get in and out of bed? ______ ______ ______ ______ 
EATING     
Are you able to:     
   - Cut your meat? ______ ______ ______ ______ 
   (X) Lift a full cup or glass to your mouth? ______ ______ ______ ______ 
   - Open a new milk carton? ______ ______ ______ ______ 
WALKING     
Are you able to:      
   (X) Walk outdoors on flat ground? ______ ______ ______ ______ 
   - Climb up five steps? ______ ______ ______ ______ 
 
 
2. Please check any AIDS OR DEVICES that you usually use for any of these activities: 
 ______ Cane                              ______ Devices used for dressing (button hook,           
                                                                zipper pull, long-handled shoe horn, etc.) 
 ______ Walker  ______ Built up or special utensils 
 ______ Crutches  ______ Special or built up chair 
 ______ Wheelchair ______Other (Specify:_____________________) 
 
3. Please check any categories for which you usually need HELP FROM ANOTHER PERSON: 
 ______ Dressing and Grooming  ______ Eating 
 ______ Arising   ______ Walking 
 
 
4. How much pain have you had OVER THE PAST WEEK?  Place a mark on the line below to 
indicate how severe your pain has been: 
 
NO PAIN   
                                                                                                                                                            PAIN AS BAD IT  
 COULD BE 
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5.    Please check the response which best describes your usual abilities OVER THE PAST WEEK: 
HYGIENE 
Without ANY 
Difficulty(0) 
With SOME 
Difficulty(1) 
With MUCH 
Difficulty(2) 
 
UNABLE  
To Do(3) 
Are you able to:     
(X) Wash and dry your body? ______ ______ ______ ______ 
   - Take a tub bath? ______ ______ ______ ______ 
   - Get on and off the toilet? ______ ______ ______ ______ 
REACH     
Are you able to:     
   - Reach and get down a 5 pound object (such as a 
         bag of sugar) from just above your head? ______ ______ ______ ______ 
   (X) Bend down to pick up clothing from the floor? ______ ______ ______ ______ 
GRIP     
Are you able to:     
   - Open car doors? ______ ______ ______ ______ 
   - Open jars which have previously been opened? ______ ______ ______ ______ 
   (X) Turn faucets on and off? ______ ______ ______ ______ 
ACTIVITIES     
Are you able to:     
   - Run errands and shop? ______ ______ ______ ______ 
   (X) Get in and out of a car? ______ ______ ______ ______ 
   - Do chores such as vacuuming or yard work? ______ ______ ______ ______ 
 
6. Please check any AIDS OR DEVICES that you usually use for any of these activities: 
 ______ Raised toilet seat   
                             ______ Bathtub bar 
 ______ Bathtub seat    
 ______ Long-handled appliances for reach 
 ______ Jar opener (for jars previously opened)             
 ______ Long-handled appliances in bathroom 
 ______ Other (Specify: __________________) 
 
7. Please check any categories for which you usually need HELP FROM ANOTHER PERSON: 
 ______ Hygiene  ______ Gripping and opening things 
 ______ Reach  ______ Errands and chores 
 
8. Considering all the ways in which illness and health conditions may affect you at this time, 
please make a mark below to show how you are doing: 
VERY                                                                                                                                                   VERY POORLY  
WELL  
 
 
 
(X) Questions of the modified HAQ
  
35 
4.2.1.5. Acute-phase reactants 
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) 
are used to determine the acute phase reactions in disease activity measures 
for RA. They also increase in other inflammatory conditions, infections and 
malignancies. Although acute-phase reactants are non-specific they correlate 
with disease activity and radiographic damage in RA (Graudal et al., 2000; 
Yildirim et al., 2004).  However, 25- 50% of patients with RA have normal ESR 
values, and more than a quarter of patients with severe or very severe RA has 
been reported to have an  ESR value of 20 mm/h or less (Wolfe & Michaud, 
1994; Sokka & Pincus, 2003b). 
CRP is more sensitive to short term changes in disease activity 
than ESR. Furthermore, ESR can be influenced by factors such as age, gender, 
fibrinogen levels, hypergammaglobulinemia, RF and anemia (Miller et al., 1983; 
Talstad et al., 1983; Kushner, 1991). CRP correlated better with other measures 
of disease activity than ESR (Mallya et al., 1982). However, CRP 
concentrations also tend to increase with age. Gender influences CRP, too, with 
higher values in women than men. (Wener et al., 2000).  
ESR and CRP have proven to be equally useful as an acute phase 
component of the ACR20 improvement criterion (Paulus et al., 1999). Originally 
DAS and DAS28 included ESR. The formula to calculate DAS28-CRP is 
suggested to provide a good estimation of DAS28-ESR values on a group level. 
However, DAS28-CRP significantly underestimates disease activity and 
overestimates the improvement of disease activity compared to DAS28-ESR 
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(Matsui et al., 2007a), and the threshold values of DAS28-CRP should be 
reconsidered (Inoue et al., 2007). CDAI is the only disease activity index without 
an acute-phase reactant (Aletaha et al., 2005a) 
 
4.2.1.6. Assessment of fatigue in RA 
Experience of fatigue has been reported by a large proportion of 
people with RA (Kirwan & Hewlett, 2007). The causality of RA fatigue is 
multidimensional, involving inflammation, pain, anemia, poor sleep and 
psychosocial factors (Wolfe et al., 1996). It has been shown that fatigue is 
strongly associated with pain (Huyser et al., 1998; Pollard et al., 2006).  
Clinically relevant levels of fatigue are present in 41- 80% of patients with RA 
(Wolfe et al., 1996; Pollard et al., 2006). However, fatigue is shown to be even 
more common in patients with fibromyalgia (Wolfe et al., 1996). Requirement of 
no fatigue is included in the ACR remission criteria (Pinals et al., 1981).  
 
4.2.1.7. Assessment of morning stiffness in RA  
Prolonged morning stiffness is regarded as a characteristic 
symptom of inflammatory arthritis and in particular of RA.  However, Yazici et al. 
(Yazici et al., 2001) observed that morning stiffness did not differ among 
patients with RA and those with osteoarthritis. Duration of morning stiffness  
exceeding 15 min is not allowed in  the ACR remission criteria (Pinals et al., 
1981). 
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4.2.2. Radiological Assessment in RA 
Radiographic imaging may be regarded as the ‘gold standard’ when 
assessing disease progression in RA (van der Heijde, 2000). Plain radiography 
of hands and feet are still performed, although newer methods such as 
magnetic resonance imaging and power-doppler ultrasound are available. 
Radiographs of hands and feet can easily be performed; they are relatively 
cheap, and standardized scoring methods have been established. 
Two major scoring systems with a number of modifications are 
available: the Larsen method (Larsen et al., 1977; Larsen, 1995; Scott et al., 
1995) and the Sharp (Sharp et al., 1971; van der Heijde, 1999) method.  In the 
original version of the Larsen method, joints of hands and feet are graded as 
follows: 0= normal, 1= slight abnormalities [periarticular soft tissue swelling, 
periarticular osteoporosis and joint space narrowing (JSN)], 2= definite early 
abnormalities, 3= medium destructive abnormalities, 4= severe definite 
abnormalities, 5= mutilating abnormalities. Each wrist is considered as one unit 
and the score is multiplied by five; the other joints included are ten DIP, eight 
PIP, ten MCP, ten MTP and two IP joints of big toes. Modifications of the Larsen 
score include omitting soft tissue swelling and osteoporosis that are often 
impossible to detect. A new grading was designed as: 0= intact bony out line 
and normal joint space, 1= erosion less than 1 mm in diameter or joint space 
narrowing, 2= one or several small erosions (diameter > 1mm), 3= marked 
erosions, 4= severe erosions: there is usually no joint space left, 5= mutilating 
changes, the original bony outlines have been destroyed (Larsen, 1995).  
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Based on the number of joints included the maximal score ranges from 100 to 
250 (Kaarela & Kautiainen, 1997; Korpela et al., 2004). A standard set of 
radiographs for grading exists.  
As the original Sharp method grades only the radiographs of hands, 
the modification of van der Heijde is applied in many studies (van der Heijde, 
1999). This modification scores the presence of erosions in 16 joints of hands 
and wrists (graded from 0 to 5), and in six joints of the feet (graded from 0 to 
10), and the presence of JSN in 15 joints of the hands and wrists (graded from 
0 to 4) and in six joints of the feet (graded from 0 to 4). The maximal grade for 
erosions is 280 units and for JSN 168; the maximum total score is 448. 
 
4.2.3. Pooled indices in disease activity assessment of RA 
As no single measure can serve as a  ‘gold standard’ to assess 
disease activity in RA, a pooled index of several individual measures is required 
(Smythe et al., 1977).  
Indices used in RCTs to document the efficacy of a treatment 
include the ACR improvement criteria (Felson et al., 1995) (presented in Table 
4), and the DAS (van der Heijde et al., 1990; van der Heijde et al., 1993) and 
DAS28 (table 5) (Prevoo et al., 1995), which provide the European League 
Against Rheumatism (EULAR) response criteria for RA (presented in Table 6). 
Recently, additional composite indices have been presented: SDAI (Smolen et 
al., 2003) and CDAI (Aletaha et al., 2005a) 
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Table 3. Measures of ACR core set of disease activity and composite indices. 
Measures ACR core 
set of 
disease 
activity 
DAS DAS28 SDAI CDAI 
Number of 
tender joints 
68 RAI (52 joints) 
28 joint 
count 
28 joint 
count 
28 joint 
count 
Number of 
swollen joints 
66 44 joint count 
28 joint 
count 
28 joint 
count 
28 joint 
count 
Patient’s 
assessment of 
pain 
VAS 0-100 - - - - 
Patient’s global 
assessment of 
disease activity 
VAS 0-100 - - VAS 0-10 VAS 0-10 
Patient’s global 
health - VAS 0-100 VAS 0-100 - - 
Evaluator’s 
(physician’s) 
global 
assessment of 
disease activity 
VAS 0-100 - - VAS 0-10 VAS 0-10 
Patient’s 
assessment of 
physical 
function 
HAQ 0-3 - - - - 
Acute phase 
reactants 
ESR/CRP 
ESR 
(formula 
for DAS-
CRP also 
available) 
ESR 
(formula for 
DAS28-CRP 
also 
available) 
CRP in 
mg/dL 
(0.1-10.0) 
- 
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4.2.4. Indices based on the American College of Rheumatology (ACR) core 
data set disease activity measures 
4.2.4.1. ACR response criteria for RA 
The ACR preliminary definition of improvement in RA (Table 4), 
published in 1995, has been widely adopted as a primary outcome measure in 
RA clinical trials (Felson et al., 1995). Validation studies have confirmed the 
ability of ACR20 to discriminate active treatment from placebo  (Pillemer et al., 
1997). The improvement in disease activity achieved in ACR20 is not very 
large, so higher thresholds for improvement such as ACR50 and ACR70 have 
also been used in clinical trials. ACR response criteria are further widely used in 
RCTs to show the efficacy of a new drug compared to placebo (Genovese et 
al., 2005; Breedveld et al., 2006; Emery et al., 2006; van der Heijde et al., 
2006).  One proposed way to use ACR response criteria is nACR, where n is 
the number of core set measures improved by ≥ 20% (Committee, 2007). 
The set of ACR improvement criteria has some shortcomings. 
Being based on a change of disease activity it cannot be used in cross sectional 
settings. Furthermore, the ACR response criteria do not recognize possible 
worsening of the patient’s status.  
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Table 4. ACR core data set for RA trials and ACR improvement criteria 
requirements       
 
ACR core set of disease activity for RA trials ACR improvement 
criteria requirements 
Tender joints ≥ 20% improvement 
Swollen joints ≥ 20% improvement 
Patient’s assessment of pain (VAS)  
Patient’s global assessment of disease activity (VAS) ≥ 20% improvement in 
3  
Physician’s global assessment of disease activity 
(VAS) 
of the 5 measures 
Patient’s assessment of physical function  
Acute-phase reactant value  
  
 
 4.2.4.2. ACR-N and the Hybrid Measure of ACR response 
ACR-N (Bathon et al., 2000) and the Hybrid Measure of ACR 
(Committee, 2007) are continuous indices based on ACR core data set 
measures and they both assess percentage change in disease activity instead 
of current disease activity in RA patients.  
The ACR-N provides a single number that characterizes the 
percentage of improvement from baseline that a patient has experienced, in 
analogy to ACR20, ACR50 and ACR70 responses. ACR-N is determined by 
calculating the smallest degree of improvement from baseline in the following 
three criteria: number of tender joints, number of swollen joints, and median 
value of the five remaining measures of the core set of disease activity 
measures. A patient with an ACR-N of X means that they have achieved an 
improvement of at least X% in tender and swollen joints and an improvement of 
at least X% in three of the other five parameters (Siegel & Zhen, 2005). ACR-N 
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can also be used to define worsening of disease by negative values.  Another 
way to apply ACR-N in a clinical trial is to compare area under curve (AUC) by 
patient over time. This approach may substantially increase the power to detect 
small differences between treatment arms (Siegel & Zhen, 2005).  
The ACR committee reevaluated the improvement criteria and 
proposed a revision of the ACR20 in 2007: the Hybrid Measure of ACR 
(Committee, 2007). This measure combines the ACR20, ACR50 and ACR70 
and is a continuous score of the mean improvement in core set measures. This 
continuous measure assesses the change of disease activity, but current 
disease activity cannot be measured. However, this new measure has greater 
statistical power to distinguish the efficacy of treatments than the ACR20 
improvement.  
 
 4.2.5. Disease Activity Score (DAS) 
Disease Activity Score (DAS) was proposed in the early nineties to 
assess disease activity in RA (van der Heijde et al., 1990; van der Heijde et al., 
1993).  DAS was developed from physician’s decisions to cease, maintain or 
start DMARDs in RA patients. DAS is a continuous index using four selected 
components. Square root and logarithm are used to provide normal distribution 
(Fransen & van Riel, 2005) (Table 5).  
The original DAS contains the Ritchie Articular Index (Ritchie et al., 
1968) (RAI, range 0-78), a 44 swollen joint count (range 0-44), ESR, and 
patient’s general health (GH) on VAS (0-100). DAS has a continuous scale from 
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0 to 10. Level of disease activity can be interpreted as low (DAS≤ 2.4), 
moderate (2.4< DAS ≤ 3.7) or high (DAS> 3.7).  DAS< 1.6 corresponds to 
remission according to the ACR remission criteria. Different versions of DAS 
include one without GH, and a version in which ESR is replaced with CRP 
(Table 5). 
DAS28 is an index derived from the original DAS with fewer joints 
included (Figure 1). DAS28 consists of a 28 tender joint count (range 0-28), a 
28 swollen joint count (range 0-28), ESR, and GH on a VAS scale (range 0-100) 
(Table 5) (Prevoo et al., 1995). DAS28 is a continuous index ranging from 0 to 
9.4. Although DAS and DAS28 cannot be directly compared, a formula to 
transform DAS to DAS28 is available (van Gestel et al., 1998).  Low disease 
activity is defined as DAS28≤ 3.2, moderate as 3.2< DAS28 ≤ 5.1, and high as 
DAS28> 5.1 (van Gestel et al., 1998). A commonly used cutoff point for 
remission is DAS28< 2.6 (Fransen et al., 2004).  
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Figure 1. Joints included in the DAS28  
 
Modifications of DAS28 include one in which ESR is substituted by 
CRP and another with only three components (GH omitted).  A recent large 
observational study indicated that values of DAS28-CRP are significantly lower 
than those of the original DAS28 (Matsui et al., 2007a). DAS28-CRP threshold 
values corresponding to remission, low disease activity, and high disease 
activity have been shown to be lower than the corresponding threshold values 
for original DAS28: 2.3 vs. 2.6, 2.7 vs. 3.2 and 4.1 vs. 5.1, respectively (Inoue et 
al., 2007). DAS formulas require complex calculations involving square roots 
and log transformations. However, calculators are easily obtained from the web 
site (DAS).  
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Table 5. Different DAS formulas 
 
Different DAS formulas  
DAS= 0.54 * sqrt (RAI) + 0.065* (SJC44)+ 0.33*Ln (ESR)+ 0.0072* GH 
DAS(3)= 0.54* sqrt (RAI) + 0.065* (SJC44)+ 0.33*Ln (ESR)+ 0.22 
DAS-CRP= 0.54* sqrt (RAI) + 0.065* (SJC44)+ 0.17*Ln (CRP+ 1)+ 0.0072*GH 
+0.45 
DAS-CRP(3)= 0.54* sqrt (RAI) + 0.065* (SJC44)+ 0.17*Ln (CRP+ 1)+ 0.65 
DAS remission< 1.6, low ≤ 2.4, moderate  >2.4 and ≤ 3.7, and high disease 
activity >3.7 
DAS28= 0.56*sqrt (TJC28)+ 0.28*sqrt (SJC28)+ 0.70*Ln (ESR)+ 0.014*GH 
DAS28(3)= [0.56*sqrt (TJC28)+ 0.28*sqrt (SJC28)+ 0.70*Ln (ESR)]* 1.08+ 0.16 
DAS28-CRP= 0.56*sqrt (TJC28)+ 0.28*sqrt (SJC28)+ 0.36*Ln( CRP+1)+ 
0.014*GH+ 0.96  
DAS28-CRP(3)= [0.56*sqrt (TJC28)+ 0.28*sqrt (SJC28)+ 0.36*Ln( CRP+1)] 
*1.10+ 1.15 
DAS28 remission< 2.6, low ≤ 3.2, moderate  >3.2 and ≤ 5.1, and high disease 
activity > 5.1 
DAS28= 1.072* DAS+ 0.932 
 
 
4.2.5.1. European League against Rheumatism (EULAR) response criteria 
In general, the efficacy of a therapy is defined by comparing means 
of changes in disease activity variables between the treatment and placebo 
groups. However, the difference between mean changes in groups of patients 
does not indicate the number of patients who have responded to treatment. 
Therefore, in addition to disease activity, the response of individual patients to 
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antirheumatic therapy is essential in clinical trials. Based on good group results 
we do not know whether a large number of patients have improved moderately 
or a small number of patients have improved substantially. 
The EULAR response criteria were based on DAS (van Gestel et 
al., 1996) and later validated on DAS28 (van Gestel et al., 1998). The EULAR 
response criteria classify patients as good, moderate or non-responders, using 
the amount of change in the DAS/DAS28 of an individual patient, and the 
DAS/DAS28 value achieved. A change of 1.2 is considered significant (Table 
6).  
A high level of agreement between ACR and EULAR improvement 
has been shown (van Gestel et al., 1999). Both can be applied in clinical trials. 
Van Gestel et. al (van Gestel et al., 1999) recommend assessing the 
components of both criteria and choosing in advance which criteria to use as 
primary and secondary endpoints.  
 
Table 6. EULAR improvement criteria 
 Value achieved Change in DAS or DAS28 from baseline 
DAS28 DAS > 1.2 >0.6 and  ≤ 
1.2 
≤  0.6 
≤  3.2 ≤  2.4 Good   
> 3.2 and  ≤ 
5.1   
>2.4 and ≤   
3.7 
 Moderate  
> 5.1 > 3.7   Non 
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4.2.6. The Simplified Disease activity index (SDAI) and the Clinical Disease 
Activity Index (CDAI)  
In addition to DAS, the currently available composite disease 
indices providing a single number on a continuous scale are the Simplified 
Disease Activity Index (SDAI) (Smolen et al., 2003) and the Clinical Disease 
Activity Index (CDAI) (Aletaha et al., 2005a). SDAI constitutes a simple 
numerical addition of individual measures on their original scale. The range of 
SDAI is 0.1- 86.0. This idea overcomes the problems of transformations and 
weighting. SDAI includes both the evaluator’s and patient’s assessments of 
disease activity. The inclusion of CRP instead of ESR was made for several 
reasons: CRP is the most reliable variable of the acute phase response and 
CRP levels have prognostic value in RA (Otterness, 1994), and CRP is less 
confounded by other factors than ESR, and has been shown to correlate better 
with other disease activity measures (Mallya et al., 1982) (Table 3. and Table 
7.). 
CDAI was derived from SDAI and is the only composite index 
without an acute phase reactant. It is also a simple sum of disease activity 
measures ranging from 0 to 76. In the validation study of CDAI, Aletaha et al. 
(Aletaha et al., 2005a) conclude that acute phase reactants add little information 
beyond the combination of clinical variables included in SDAI. The authors 
suggest that CDAI will prove of greatest value in clinical practice rather than 
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research, where acute phase reactants are nearly always available (Table 3 
and Table 7).  
SDAI and CDAI are feasible indices for which a calculator is not 
necessary. They are also easy to understand for the patient, which may 
improve outcomes, as has been the case in other chronic diseases (Egan et al., 
2003; Rachmani et al., 2005).  
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Table 7. Formulas for the Simplified Disease Activity Index and the Clinical 
Disease Activity Index 
 
SDAI and CDAI 
SDAI= SJC28+ TJC28+ PGA+ EGA+ CRP (in mg/dl) 
CDAI= SJC28+ TJC28+ PGA+EGA 
 
PGA= patient’s global assessment of disease activity VAS 0-10 
EGA= evaluator’s global assessment of disease activity VAS 0-10 
CRP range 0.1- 10.0, CRP more than 10 are replaced by value 10 
   
  
4.2.7. Patient self-report outcomes (PRO) indices 
It has been shown that RA patients are reliable and accurate 
reporters of their own symptoms and signs (Stewart et al., 1990; Mason et al., 
1992). Rheumatologists have rated examination of joints the most important 
measure of disease activity in both randomized trials and clinical care (Wolfe et 
al., 2003). Nonetheless, most visits to rheumatologists do not include a formal 
quantitative joint count (Pincus & Segurado, 2006). A practical quantitative 
index, like the patient self report joint count, to monitor clinical status without 
formal joint counts by the rheumatologist could be of considerable value in a 
busy clinical setting (Pincus et al., 2007a). The value of such an index in 
discriminating active and control treatments has also been confirmed  (Pincus et 
al., 2006). On this basis, the use of patient reported outcome indices has been 
suggested to be useful both in clinical work and clinical trials.  
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The Rapid Assessment of Disease Activity in Rheumatology 
(RADAR) questionnaire is a one page (2 sides) questionnaire about disease 
activity, clinical status and joint pain/tenderness, which includes six items and 
can be completed by the patient alone (Mason et al., 1992). The Rheumatoid 
Activity Index (RADAI) is also a self-administered questionnaire based on 
RADAR, and it combines five items in a single index. The items ask the patient 
about their 1) global disease activity in the last six months, 2) disease activity in 
terms of current tender and swollen joints, 3) arthritis pain, 4) duration of 
morning stiffness, and 5) tender joints to be rated in a joint list. The first three 
items are rated from 0 to 10, and duration of morning stiffness from 0 to 6, and 
tender joints from 0 to 48, but are transformed into a single 0 to 10 scale. The 
values of items are summed and divided by the number of items.  The original 
goal of the RADAI was to provide an easily used assessment of disease activity 
in RA (Stucki et al., 1995). 
The Patient Activity Scale (PAS) is composed of pain VAS, patient 
global VAS, and the HAQ. The index is formed by multiplying HAQ by 3.33 and 
dividing the sum of these items by three (Wolfe et al., 2005a). Pincus et al. 
(Pincus et al., 2003) reported already in 2003 a similar index, and  showed its 
ability to distinguish active treatment from placebo. It was later named RAPID 3. 
RAPID 4 adds a RADAI self-report joint count to RAPID 3. The RADAI score 
scale of 0- 48 is converted to 0- 10. The raw RAPID is divided by four to give a 
score of 0- 10 (Pincus et al., 2007a). Pincus et al. (Pincus et al., 2007b) 
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proposed a continuous quality improvement strategy based on routine 
assessment of patient index data (RAPID) scores in standard clinical care.  
 
4.3. Remission in RA      
No single definition for remission exists and several criteria for 
remission have been developed. Previously, definitions of remission included 
phrases such as “full recovery” (Corrigan et al., 1974), “no joint swelling” (Sharp 
et al., 1982), “absence of swollen joints or tender joints” (McCarty et al., 1995), 
“inactive disease” (Duthie et al., 1957), “complete control of synovitis and 
normal erythrocyte sedimentation rate” (Sambrook et al., 1982), and “being 
symptom free” (Nissilä et al., 1983; Wolfe et al., 1993). In some studies 
remission has been an outcome without any definition (Csuka et al., 1986; 
Williams et al., 1992; Hannonen et al., 1993).  
Remission is usually defined using ACR remission criteria or is 
based on a continuous disease activity index with a cutoff point for remission 
usually derived from the ACR remission criteria. This means that most patients 
with disease activity below that cutoff point are in remission, but some may still 
have active disease (Aletaha et al., 2005b; Mierau et al., 2007). Composite 
indices with a cutoff point for remission include DAS, DAS28, SDAI and CDAI. 
In addition to cross sectional remission, sustained remission has been studied 
(van der Heijde et al., 2005; Listing et al., 2006; Mierau et al., 2007). 
 
  
52 
4.3.1. ACR remission criteria        
Preliminary remission criteria for RA were proposed by a committee 
of ARA (now ACR) in 1981 (Pinals et al., 1981) (Table 8). To develop these 
criteria, 35 rheumatologists were asked to collect information from 35 RA 
patients concerning symptoms, laboratory data, and information on results of 
joint examination. These rheumatologists then classified patients into four 
categories: complete remission without drugs, complete remission with drugs, 
partial remission, and active disease. These variables were analyzed to select 
those that best discriminated patients in remission from those with active 
disease. Of these criteria sets tested among RA patients in remission or with 
partial remission or active disease, six criteria were chosen. If four of the criteria 
were met, sensitivity was 90% and specificity 69% for complete remission. If 
five of the criteria were met, the corresponding figures were 72% and 92%. A 
duration requirement of two months was chosen, as 90% of patients in 
remission fulfilled this criterion. The use of the ACR remission criteria has been 
heterogeneous; requirement of no fatique is often omitted and the number of 
criteria required for remission varies among different studies.  
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Table 8. The ACR criteria for clinical remission in rheumatoid arthritis (Pinals et 
al., 1981). 
 
 Five or more of the following requirements must be fulfilled for at least 
two consecutive months 
1. Duration of morning stiffness not exceeding 15 minutes  
2. No fatigue 
3. No joint pain (by history) 
4. No joint tenderness or pain in motion 
5. No soft tissue swelling in joints or tendon sheaths 
6. Erythrocyte sedimentation rate (Westergren method) less than 30 
mm/hour for a female or 20 mm/hour for a male 
 
4.3.2 Remission criteria based on DAS  
DAS (van der Heijde et al., 1990; van der Heijde et al., 1993) and 
its modified version DAS28 (Prevoo et al., 1995) including 28 joints were 
developed to assess disease activity in RA.  Cutoff points for both indices 
corresponding to the ACR remission criteria have been defined. Prevoo et al. 
(Prevoo et al., 1996) compared ACR and DAS remission criteria with the 
observation that DAS<1.6 corresponds to ACR remission criteria.  A remission 
cut point of DAS28<2.6 was found to correspond to DAS <1.6 based on a 
formula developed to convert DAS to DAS28 (van Riel & van Gestel, 2000), and 
therefore DAS28<2.6 has been used to define remission in RA. In the study of  
Fransen et al. (Fransen et al., 2004) DAS28< 2.6 corresponded with fulfillment 
of the modified ACR remission criteria. DAS28-CRP remission was used as the 
outcome measure in one RCT (Genovese et al., 2008).  
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4.3.3. Remission criteria based on simplified disease activity indices 
Aletaha et al. (Aletaha & Smolen, 2005) analyzed ratings of RA 
patients by expert rheumatologists for disease activity to define a cutoff point for 
SDAI and CDAI remissions. The cutoff points for remission for SDAI and CDAI 
were defined as 3.3 and 2.8, respectively.  
 
4.3.4. Radiographic remission 
Radiographic imaging may be regarded as the ‘gold standard’ for 
assessing disease progression in RA (van der Heijde, 2000). The Food and 
Drug Administration (FDA) has formulated the most rigorous definition of 
remission: ACR remission criteria must be met in addition to radiological arrest 
of joint damage progression (Sharp/van der Heijde or Larsen method). These 
criteria include a time period requirement of six months (Sesin & Bingham, 
2005; van der Helm-van Mil  AHM, 2006).  
Jäntti et al. (Jäntti et al., 2001) assessed radiographs of hands and 
feet over 20 years according to the Larsen score (scale 1–100). If the score did 
not increase more than one point compared to radiographs taken 5–19 years 
earlier, the patient was considered to be in radiographic remission; the 
radiographic remission rate was 26% at 20 years.  
 
4.4. Minimal disease activity for RA (MDA)    
                   The need for a definition of MDA for patients with RA originated 
from the observation that achieving and maintaining low disease activity is 
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probably more important in the long term than the high percentage improvement 
from very high disease activity level which was documented in many RCTs. 
Furthermore, strict remission is not a common feature in clinical practice. The 
threshold for MDA is between moderate disease activity and remission and 
according to the definition anyone in remission will also be in MDA (Wells et al., 
2005).   
              All patients with no swollen joints, no tender joints and ESR≤ 10 mm/h 
are in MDA. Besides, MDA has two different definitions: the core set definition 
(Figure 2) and DAS28 definition (Figure 3).  The DAS28 defines that patients 
are in MDA when DAS28 ≤ 2.85. According to the core set definition five of 
seven of the following criteria have to be fulfilled: 1) pain (0-10) ≤ 2; 2) swollen 
joint count (0-28) ≤ 1; 3) tender joint count (0-28) ≤ 1; 4) Health Assessment 
Questionnaire (HAQ 0-3) ≤ 0.5; 5) physician global assessment of disease 
activity (0-10) ≤ 1.5; 6) patient global assessment of disease activity (0-10) ≤ 2; 
7) ESR ≤ 20 (Wells et al., 2005).  
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Figure 2. The core set definition for minimal disease activity for RA. Pain ≤ 2; 
swollen joint count (SJC) ≤ 1; tender joint count (TJC) ≤ 1; Health Assessment 
Questionnaire (HAQ) ≤ 0.5; physician global assessment ≤ 1.5; patient global 
assessment ≤ 2; ESR ≤ 20 mm/h.  
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Figure 3. The DAS based definition for minimal disease activity for RA. SJC: 
swollen joint count; TJC: tender joint count; ESR: erythrocyte sedimentation 
rate; DAS: disease activity score
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4.5.  Remission rates in selected clinical cohorts and randomized clinical 
trials  
ACR remission criteria have been used in randomized clinical trials 
concerning traditional DMARDs, with remission rates of 7% to 37% (Wolfe & 
Hawley, 1985; Möttönen et al., 1999; Ferraccioli et al., 2002; Gerards et al., 
2003; Korpela et al., 2004), and in clinical cohorts with  remission rates of 0%  
to 32% (Suarez-Almazor et al., 1994; Möttönen et al., 1996; Eberhardt & Fex, 
1998; Young et al., 2000; Lindqvist et al., 2002; Khanna et al., 2007).  The ACR 
remission criteria have not been used in RCTs of biological agents. 
The FIN-RACo trial used a rigorous modification of the ACR 
remission criteria, requiring all five criteria (fatigue excluded) to be met. 
Nonetheless, after two years, 37% of the patients who received therapy with a 
combination of methotrexate, sulfasalazine, hydroxychloroquine and 
prednisolone were in remission (Möttönen et al., 1999).   
DAS28 remission levels from 15% to 53% (St Clair et al., 2004; 
Breedveld et al., 2006; van der Heijde et al., 2006; van Riel et al., 2006; 
Mancarella et al., 2007) were found in several clinical trials using biological 
agents, and were highest in patients treated with a combination of methotrexate 
and a biological agent (infliximab, etanercept or adalimumab).  In the PREMIER 
study (Breedveld et al., 2006), the remission rate at two years was 25% when 
adalimumab was used alone and 49% when it was used in combination with 
methotrexate. In the TEMPO trial (van der Heijde et al., 2006) remission rates 
were 29.6% (etanercept as a single agent) and 53.7% (etanercept in 
combination with methotrexate).  The remission rate was 31% at one year in the 
  
59 
study of St Clair et al.(St Clair et al., 2004) in RA patients who were treated with 
a combination of methotrexate and infliximab (dose 6 mg/kg). In the abatacept 
study, patients with inadequate response to anti-TNF therapy were treated with 
abatecept for two years. Remission was assessed according to (DAS28-CRP< 
2.6) with remission rates at six months and two years of 11% and 20%, 
respectively (Genovese et al., 2008). 
Mierau et al. (Mierau et al., 2007) studied sustained remission in 
RA patients. Sustainability of remission was defined as remission at two 
consecutive visits. Four different definitions were used: modified ACR remission 
(four of the five items had to be met, fatigue excluded), DAS28 remission, and 
SDAI and CDAI remission. The proportion of patients in remission at any one of 
the two visits was highest for DAS28 (43%), followed by modified ACR 
remission (39%) and SDAI and CDAI remission (34% each). Sustained 
remission was observed in much lower proportions of patients (between 17 and 
20 depending on the instrument.). Van der Heijde et al. (van der Heijde et al., 
2005) studied sustainability of DAS and DAS28 remissions and ACR70 
response in the TEMPO trial, which  compared the efficacy of combined  MTX 
and etanercept therapy to the efficacy of these drugs as monotherapies in 
patients with advanced RA. Remission was assessed at four-week intervals or 
less frequently over one year.  Patients treated with combination therapy scored 
better than those treated with either of the monotherapies with respect to the 
number of remission periods and sustainability of remissions.    
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5. AIMS OF THE STUDY 
The purposes of the present study were to examine the methods 
used to assess disease activity and remission in RA, and to develop a new 
continuous index for the measurement of disease activity in RA.  
More precisely, the study set out to answer the following questions: 
 
1) What is the frequency of remission at five years after diagnosis when 
three sets of criteria are used in patients with RA in an inception cohort? 
2) Is remission more often sustained in RA patients treated with a 
combination of traditional DMARDs and prednisolone compared to 
patients treated with a single DMARD with or without prednisolone? 
Does sustained remission protect against radiographic progression? 
3) Is DAS28 an appropriate tool to assess remission in patients with RA?  
4) What is the influence of components of DAS28 (tender joint count, 
swollen joint count, patient’s general health and erythrocyte 
sedimentation rate) on the total DAS28 score? Does overlapping occur in 
the four individual components in RA patients with low, moderate or high 
disease activity? 
The final study aim was: 
5) To develop a new disease activity index for RA based on the American 
College of Rheumatology Core set of disease activity measures.   
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6. PATIENTS AND METHODS 
6.1. Selection of patients and study design 
Two different patient populations were chosen for this study: 
patients from a clinical cohort and patients from an RCT comparing two different 
treatment strategies. 
 
6.1.1. The clinical cohort patients 
Jyväskylä Central Hospital is the only rheumatology center in the 
Central Finland District; it served a population of 270,000/ year in 2007 
(250 000/ year in 1997). All new RA patients in this area are referred to the 
hospital for diagnosis and initiation of treatments. All new inflammatory arthritis 
patients older than 16 years who did not meet criteria or show clinical signs of 
other specific arthritides (crystal deposit disease and spondylarthropathies) 
were included in the RA 1997 inception cohort. A total of 127 patients were 
included in the study. These patients received rheumatology care at Jyväskylä 
Central Hospital for two years after the diagnosis by a multidisciplinary team, 
and were subsequently invited to participate in a five-year study.  Later, 110 
patients whose diagnosis was made in 1998 were also included in the study 
cohort. At this stage a subgroup of patients (161 of 237 patients with clinical 
diagnosis of early RA) who cumulatively fulfilled the ARA criteria for RA was 
analyzed. Disease-modifying anti rheumatic drugs (DMARDs) were started at 
the time of the diagnosis. The target of therapy was clinical remission. 
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Measures at baseline and at two and five years included: 68 tender 
and 66 swollen joint counts (Felson et al., 1993); laboratory tests including ESR, 
CRP, and RF; self-report pain and global health on 100 mm VAS, functional 
capacity according to the HAQ, morning stiffness in minutes on self-report; and 
radiographs of the hands and feet. Wrists, I-V metacarpophalangeal (MCP) 
joints, I-V metatarsophalangeal (MTP) joints and interphalangeal (IP) joints of 
the big toes were assessed according to the Larsen score  (Larsen et al., 1977; 
Kaarela & Kautiainen, 1997). Medications were recorded at each visit. The date 
of initiation and discontinuation of each DMARD was recorded.  
 
6.1.2. The Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) 
patients 
In the FIN-RACo study (Möttönen et al., 1999) 195 patients with 
recent onset RA were randomized to receive either DMARD combination 
therapy (COMBI) or  DMARD monotherapy (SINGLE). Patients with previous 
DMARD therapy or those who had taken glucocorticoid therapy within two 
weeks prior to enrollment were excluded. The inclusion criteria were: age 
between 18 and 65 years, duration of symptoms less than two years, active 
disease with ≥ three swollen joints, and at least three of the following: ESR ≥28 
mm/h or CRP >19mg/L, morning stiffness ≥ 29 min, > five swollen joints, and 
>10 tender joints. All patients had to fulfill the ARA criteria for rheumatoid 
arthritis (Arnett et al., 1988; Möttönen et al., 1999). 
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The goal of treatment was remission in both groups. In the COMBI 
group, the initial DMARDs were sulfasalazine (SSZ) 500 mg twice daily, 
methotrexate (MTX) 7.5 mg/ week, and hydroxychloroquine (HCQ) 300mg daily.  
Prednisolone 5 mg daily was instituted simultaneously with the DMARDs. Drug 
doses were adjusted if a patient did not improve by 50% or more in two of the 
three criteria: number of swollen joints, number of tender joints, and ESR or 
CRP. The highest doses allowed were SSZ 2 g/day, MTX 15 mg/week, HCQ 
300 mg/day, and prednisolone 10 mg/day. SSZ or HCQ could be replaced by 
auranofin (3-6 mg/day) and MTX by azathioprine (2 mg/kg/day) if the former 
drugs were discontinued either for inefficacy or adverse effects. 
In the SINGLE arm the treatment was performed according to the 
“sawtooth” strategy (Fries, 1990; Sokka & Hannonen, 1999) with remission as 
the target. The first DMARD was SSZ 2g/day and the dose could be increased 
up to 3g/day. Simultaneous oral prednisolone treatment was not mandatory, but 
it was allowed up to 10 mg/ day at the discretion of the treating rheumatologist. 
SSZ could be replaced by MTX (or other single DMARD) in the case of an 
adverse event or lack of efficacy.  
Intraarticular glucocorticoid injections were allowed according to the 
judgment of the attending physician in all patients (Möttönen et al., 1999).  
Patients were evaluated at baseline, and at six, 12 and 24 months. 
Clinical assessments included tender joint count (68 joints) and swollen joint 
count (66 joints), duration of morning stiffness in minutes, physician’s and 
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patient’s overall assessments and pain on VAS (0-100 mm), physical function 
on patient self report (HAQ), ESR and CRP. 
Radiographs of hands and feet were taken at baseline, and at six 
and 24 months. Radiographs of 163 patients were available at baseline. 
Radiographs were assessed  blinded to the clinical data, and were scored 
according to the Larsen method (0-200) (Larsen et al., 1977), including  I-V 
MCP and I-V PIP joints of both hands, II-V MTP joints, IP joints of big toes, and 
wrists (multiplied by five), with a total score of 200. 
 
6.1.3. Definitions of remission  
We used four separate sets of criteria to define remission, as 
shown in Table 9. The ACR remission criteria require: 1) no joint or tendon 
sheet swelling, 2) no joint tenderness, 3) normal ESR, 4) morning stiffness ≤ 15 
minutes, and 5) no joint pain by history (we used VAS ≤10 mm on a scale of 1-
100 mm)(Sokka & Pincus, 2003b). The requirement of fatigue was excluded, 
but the five criteria above had to be fulfilled. Clinical remission was defined as: 
1) no tender and 2) no swollen joints, and 3) normal ESR. Radiographic 
remission was defined as: 1) no worsening of erosions, and 2) no new erosions 
from baseline to five years. DAS28 remission was defined as DAS28< 2.6.  
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6.1.4. Definition of sustained remission 
Sustained remission indicates remission at six, 12, and 24 months.  
Sustainability of remission was expressed as the percentage of patients in 
sustained remission at each visit. 
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Table 9. Remission criteria used in this study 
Remission criteria 
Modified ACR remission criteria (criteria 1 to 5 must be fulfilled) 
1. No joint swelling or soft tissue swelling of tendon sheets 
2. No joint tenderness or pain on motion 
3. Normal ESR of < 30 in women and < 20 in men 
4. Morning stiffness of 15 minutes or less 
5. Absence of joint pain by history interpreted as pain VAS score ≤10 on a scale of 
1-100 
(6. Absence of fatigue) 
DAS28 remission 
DAS28 < 2.6 
Clinical remission 
1. No joint swelling 
2. No joint tenderness or pain on motion 
3. Normal ESR 
Radiographic remission 
1. No worsening of erosions 
2. No new erosions from baseline to five years 
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6.1.5. Definitions of disease activity indices and overlapping (distribution 
of values of individual variables between defined disease activity states) 
6.1.5.1. DAS28 
DAS28 was calculated with the formula 0.56 × SQRT (tender joints 
28) + 0.28 × SQRT (swollen joints 28) + 0.70 × ln (ESR) + 0.014 × GH (van 
Gestel et al., 1996). 
Disease activity was graded as follows: low disease activity DAS28 
≤ 3.2, moderate disease activity DAS28 > 3.2 and ≤ 5.1, and high disease 
activity DAS28 > 5.1(van Gestel et al., 1999).  
 
6.1.5.2 Effects of the individual components of DAS28 on the total DAS28 
score (‘theoretical model’) 
Using a ‘theoretical model’ the effects of the individual components 
of DAS28 (TJC, SJC, ESR, and GH) were calculated according to the DAS28 
formula. In the model it was presumed that the other three components 
remained at 0 (ESR 1) while the value of the component studied varied from 0 
(ESR 1) to its clinically relevant maximum. The effect of TJC was calculated as 
follows: 0.56 × SQRT (range from 0 to 28) + 0.28 × SQRT 0 + 0.70 × ln 1 + 
0.014 × 0; the effect was calculated similarly for the other three components.  
 
6.1.5.3. Definition of overlapping 
Overlapping was calculated as follows. The higher limit for 
overlapping was defined as the highest SJC (on a 66 joint count) in the low 
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disease activity group, and the lower limit as the lowest SJC in the high disease 
activity group; the percentage of patients who fell between these limits 
represents overlapping in SJC. Overlapping was calculated similarly for TJC (on 
a 68 joint count), ESR and GH. 
 
 6.1.6. The Mean Overall Index for RA (MOI-RA) 
The MOI-RA is the mean of standardized values of tender and 
swollen joint counts (28, 42 or 66/68 joint counts), patient’s (GH) and 
physician’s (GL) assessments of global health, and patient’s assessment of 
pain on VAS (0-100 mm], the HAQ (0-3), and ESR (1-100). In ESR, all values 
above 100 are replaced by 100. Standardization means that the effect of an 
individual component on the total score is equal: the HAQ value (range 0-3) is 
divided by its maximum, which is 3,  and multiplied by 100. Similar calculations 
are performed with the other components: they are standardized to range from 
0 to 100. The mean of the standardized values is calculated. The range of MOI-
RA is 0-100; higher values indicate poorer outcomes. If values of 1-3 
components of MOI-RA are missing, standardized values are calculated from 
the available component values and the mean of the standardized values is 
recorded. 
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7. STATISTICAL ANALYSIS 
The results were presented as mean and median, standard 
deviation (SD) or interquartile range (IQR), percentages and 95% confidence 
intervals (CI). 
 
7.1. Statistical analysis (Study I) 
The agreement of the remission criteria was tested using the 
Jaccard test, which calculates the proportion of positive observations in both 
variables (the ACR and clinical remission criteria) over positive observations in 
either variable (the ACR or clinical remission criteria). Cochran’s Q was used to 
test the equality of the remission proportions in the three dichotomous remission 
criteria variables. 
 
7.2. Statistical analysis (Study II) 
The sustainability of treatment response was analyzed by applying 
generalized estimating equation (GEE) models with an exchangeable 
correlation structure. Odds ratios with confidence intervals were based on the 
GEE models with baseline disease activity on DAS28 as a covariate.  
The median change in the Larsen score from baseline to two years 
is presented with Hodges-Lehmann estimates (Hollander & Wolfe, 1999).  
Permutation type analysis of covariance with baseline radiographic scores as 
covariates was applied to compare radiographic progression between the 
groups concerning remission.  
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7.3. Statistical analysis (Study III) 
Receiver operating characteristic (ROC) curves were constructed to 
determine the cutoff point of DAS28 with the highest possible sensitivity and 
specificity corresponding to the ACR remission criteria and clinical remission 
criteria. The 95% confidence intervals for the areas under ROC were obtained 
by bias corrected and accelerated bootstrapping.   
Sensitivity, specificity, positive predictive value, likelihood ratio, and 
their 95% CI values were calculated for each of the remission criteria. 
 
7.4. Descriptive statistics (Study V) 
Distributions of MOI-RA and DAS28 were represented as skewness and 
kurtosis. The coefficient of variation was calculated for both indices using the 
formula: (SD/mean value of index at baseline) x 100. Confidence intervals (95% 
CI) were obtained from bias corrected bootstrapping (5000 replications). 
Assumptions of normality in the baseline index values were evaluated by the 
Kolmokorov-Smirnov test with Monte Carlo p-values.  The internal consistency 
between components of MOI-RA was estimated by calculating Cronbach’s 
alpha, and the reproducibility of MOI-RA by calculating the intra class 
correlation coefficient (ICC). 
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7.5. Criterion validity (Study V) 
MOI-RA was compared both with ACR response criteria and 
DAS28. The mean change in MOI-RA from baseline to six months was 
calculated in patients 1) who did not meet ACR20 response criteria, and 2) in 
patients who met ACR20 but not ACR50 response, 3) ACR50 but not remission, 
and 3) in patients who met ACR remission criteria. Possible relationships 
between MOI-RA and different ACR response classes were studied using 
analyses of covariance (ANCOVA). Agreement between MOI-RA and DAS28 
was tested using Pearson’s correlation coefficient. 
 
7.6. Responsiveness (Study V) 
Responsiveness was calculated as the standardized response 
mean (SRM) and effect size (ES). SRM was defined as the mean change of the 
score from baseline divided by the standard deviation (SD) of this change 
(Liang et al., 1985). ES was defined as the mean change from baseline divided 
by the SD of the baseline score (Kazis et al., 1989). Confidence intervals of ES 
and SRM values were obtained by bias corrected bootstrapping (5000 
replications).  
   
7.7. Sensitivity to change (Study V) 
The sensitivity to change of the MOI-RA index was analyzed in the 
FIN-RACo patient population from baseline to six months, and compared to 
DAS28. To be able to include all information on the patient population at all time 
  
74 
points (baseline, six and 12 months) repeated measures analyses were 
performed using generalized linear mixed models. 
 
8. RESULTS 
8.1. The clinical cohort and the FIN-RACo trial patients 
The clinical cohort included 127 early RA patients diagnosed at 
Jyväskylä Central Hospital in 1997; 111 of these patients attended the five-year 
control visit (Study I). A further 110 patients diagnosed in 1998 were also 
included in the clinical cohort. A total of 196 patients diagnosed in 1997-1998 
(237 patients at baseline) attended the five-year visit and 161 of those 
diagnosed in 1997-1998 cumulatively fulfilled the ACR criteria for RA and were 
included in the analysis (Study III). Patients were actively treated with DMARDs 
and the goal of treatment was remission. DMARD therapy was started from the 
diagnosis.   
Patients from a RCT were also analyzed: the original FIN-RACo 
study included 195 patients: 97 were in the COMBI arm and 98 in the SINGLE 
arm. The mean age of all patients was 47 years, 62% were female, 70% were 
rheumatoid factor positive, and 48% of the patients had erosions in hand and/or 
feet radiographs at baseline. The present analyses include 169 patients with 
complete data (79 COMBI, 90 SINGLE) who were assessed for remission and 
good treatment response at six, 12 and 24 months (Table 10)(Study II, IV and 
V). 
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Table 10. Comparison of demographic variables and disease characteristics of 
all patients at baseline in the FIN-RACo trial and patients included in this 
analysis  
 
 All 195 
patients 
169 patients analyzed for sustained 
remission 
  Total 
169 patients 
COMBI 
79 patients 
SINGLE 
90 patients 
Mean age, years (SD) 47 (10) 47 (10) 46 (9) 48 (10) 
Female gender (%) 121 (62%) 106 (63%) 47 (60%) 59 (66%) 
Patients with positive 
rheumatoid factor (%) 
136 (70%) 120 (71%) 58 (73%) 62 (69%) 
Patients with erosions (%) 94 (48%) 83 (49%) 36 (46%) 47 (52%) 
Duration of symptoms 
before diagnosis, months, 
median (IQR) 
6 (4, 10) 6 (4, 10) 6 (4, 9) 7 (4, 11) 
Tender joints, median 
(IQR) 
17 (13, 25) 17 (13, 24) 16 (13, 23) 17 (13, 24) 
Swollen joints, median 
(IQR) 
13 (9, 16) 13 (9, 16) 13 (9, 16) 13 (9, 16) 
Patient global assessment, 
median (IQR) 
48 (31, 64) 47 (29, 61) 47 (28, 61) 47 (31, 61) 
 
Physician global 
assessment 
44 (31, 59) 42 (31, 59) 38 (31, 52) 46 (30, 63) 
DAS28, mean (SD) 5.6 (1.0) 5.6 (1.0) 5.4 (0.9) 5.7 (1.1) 
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8.2. Remission in RA 
In the clinical cohort 19 [17 %( 95% CI 11% to 25%)] of the 111 
examined patients diagnosed in 1997 as having RA met the ACR remission 
criteria, 41 patients [37% (95% CI 28% to 47%)] met the clinical remission 
criteria (no tender, no swollen joints and normal ESR), and 61 patients [55% 
(95% CI 49% to 68%)] met the radiographic remission criteria (no worsening of 
erosions and no new erosions from baseline to five years). Only 13 [12% (95% 
CI 6% to 19%)] patients met all three sets of remission criteria and 74 [67% 
(95% CI 57% to 75%)] met at least one of the criteria (Figure 4)(Study I). 
The similarity between the criteria was 0.46 (95% CI 0.31 to 0.29) 
for the ACR versus clinical remission, 0.19 (95% CI 0.10 to 0.29) for the ACR 
versus radiographic remission, and 0.38 (95% CI 0.27 to 0.49) for clinical 
versus radiographic remission criteria. The rate of remission was statistically 
different between the three sets of remission criteria according to Cochran’s Q 
(p < 0.001)(Study I). 
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Figure 4. Remission in 111 patients with early RA five years after onset of 
disease  
 
When the RA patients diagnosed in 1997 and 1998 were included, 
at five years 19 (12% [95% CI 7% to 18%]) of the 161 examined RA patients 
met the ACR remission criteria, including 106 (66%) with no swollen joints, 69 
(43%) with no tender joints, 119 (74%) with normal ESR, 65 (40%) with morning 
stiffness ≤15 minutes, and 32 (20%) patients with no pain (Table 11). A total of 
55 patients [34% CI 27% to 42%] met the simple set of clinical remission criteria 
at five years (Study III).  
The positive predictive value for the ACR remission criteria was 
lowest for normal ESR (16%), and highest for no history of joint pain (56%). 
Similarly, the likelihood ratio was lowest for normal ESR (1.40) and highest for 
no joint pain (10.0). According to the less rigorous ACR remission criteria (four 
of the five ACR remission criteria had to be fulfilled and fatigue was excluded), 
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40 [25% (95%CI 19% to 33%)] of the patients were in remission at five years 
(Table 11)(Study III).  
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In the clinical cohort, only 23 patients [21 %( 95% CI 14% to 29%)] 
were in clinical remission both at two and five years (Study I). In the FIN-RACo 
trial, 20 (25%) of the COMBI patients were in ACR remission at six months, of 
whom 13 and 11 patients were also in remission at 12 and 24 months, 
respectively. The corresponding figures were 11 (12%), three and three for the 
SINGLE patients. Thus, remission was sustained in 11 [14% (95% CI 7% to 
23%)] COMBI and three [3% (95% CI 1% to 9%)] SINGLE patients (p=0.013) 
(Figure 4). The odds ratio for COMBI vs. SINGLE patients to be in sustained 
ACR remission was 4.61 (95% CI 1.17 to 16.99), adjusted for baseline DAS28 
values (Study II). 
The sustainability of DAS28 remission was analyzed in the FIN-
RAco trial patients: a total of 40 [51% (95% CI 39% to 62%)] COMBI and 14 
[16% (95%: CI10% to 24%)] SINGLE patients (p<0.001) met sustained DAS28 
remission (Figure 5)(Study II). 
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Figure 5. Percentage of patients in sustained ACR remission and DAS28 
remission in COMBI and SINGLE therapy groups in the FIN-RACo trial 
 
 
Sustainability of remission and good treatment response and their 
influence on radiographic progression is presented in Table 12. 
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Table 12. Radiographic progression and sustainability of remission and good 
treatment response in the 163 patients of the FIN-the RACo trial with 
radiographs over two years  
  
 
 
† Remission at six, 12 and 24 months. ‡ Hodges-Lehman estimates of median 
difference.  * Permutation-type analysis of covariance. Baseline values are used 
as covariates. ● Good treatment response at six, 12 and 24 months. 
Improvement criteria Number 
of 
patient 
Baseline 
Larsen 
median 
(IQR) 
Change in 
Larsen score from 
0 to 24 months 
median (95%CI)‡ 
P-
value* 
ACR remission    0.017 
No remission at six months 132 2 (0, 6) 4 (2 to 8)  
Remission at six months, 
no sustained remission 
17 2 (0, 8) 4 (0 to 10)  
Sustained remission† 14 0 (0, 3) 0 (0 to 2)  
DAS28 remission     <0.001 
No remission at six months 82 0 (0, 4) 6 (2 to 10)  
Remission at six months, 
no sustained remission 
30 2 (0, 10) 4 (2 to 16)  
Sustained remission† 51 2 (0, 6) 1 (0 to 2)  
DAS28 good treatment 
response  
   <0.001 
No good treatment response 
at six months 
62 0 (0, 4) 6 (2 to 10)  
Good treatment response at 
six months; no sustained 
good response 
28 4 (0, 9) 10 (4 to 16)  
Sustained good treatment 
response●  
73 0 (0, 5) 1 (0 to 6)  
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                 The ROC curves of DAS28 were used to define the presence or 
absence of remission in the clinical cohort using the modified ACR criteria and 
the clinical remission criteria (Figure 6). The area under ROC was 0.87 (95% CI 
0.82 to 0.93) for the ACR remission criteria, 0.90 (95% CI 0.84 to 0.94) for the 
clinical remission criteria and 0.89 (95% CI 0.83 to 0.94) for the less rigorous 
ACR remission criteria (Study III).  
The cutoff value for DAS28 was 2.32 (sensitivity 100%, specificity 
73%) for the modified ACR remission criteria, 2.60 (sensitivity 93%, specificity 
76%) for the less rigorous set of the ACR remission criteria, and 2.68 (sensitivity 
91%, specificity 79%) for the clinical remission criteria (Study III). 
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Table 13. The estimated cutoff points of DAS28 corresponding to the ACR and 
the clinical remission criteria 
 
 
●ACR remission criteria, all five criteria must be fulfilled (fatigue excluded) 
╬ACR remission criteria, four of the five criteria must be fulfilled (fatigue 
excluded) 
† Area under the ROC curves with 95% confidence interval obtained by bias 
corrected and accelerated bootstrapping (5000 replications).  
‡ Positive predictive value (proportion of the subjects with positive test results 
who were in remission). 
* Likelihood Ratio Positive (ratio of the sensitivity of a test to its false-positive 
error rate). 
Characteristics Remission criteria 
 ACR● (95% CI) ACR╬ (95% CI) Clinical (95% CI) 
Cut-off point 2.32 2.60 2.68 
Area under 
ROC† 
0.87 (0.82 to 0.93) 0.89 (0.83 to 0.94) 0.90 (0.84 to 0.94) 
Sensitivity, % 100 (82 to 100) 93 (80 to 98) 91 (80 to 97) 
Specificity,% 73 (64 to 80) 76 (67 to 83) 79 (70 to 87) 
PPV‡, % 33 (21 to 46) 56 (43 to 68) 69 (57 to 80) 
LR+* 3.64 (2.66 to 4.71) 3.80 (2.76 to 5.32) 4.38 (3.05 to 6.48) 
  
85 
 
False-positive Probability (1-Specificity)
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0
S
en
si
tiv
ity
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
ACR remission
Clinical remission
 
 
 
 
 
 
Figure 6. ROC curves of DAS28 when used to define the presence or absence 
of the ACR remission criteria and the clinical remission criteria  
 
 
Of the 57 patients who had DAS28<2.32, five (9%) had tender 
joints, four (7%) had swollen joints, and two (4%) had both tender and swollen 
joints on the 28 joint count. On the 66 joint count the corresponding figures were 
11 (19%), six (11%) and four (7%) (Table 15). If we had used the previously 
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proposed cutoff point of 2.6 as the limit of DAS28 remission in our cohort, a 
higher proportion of our patients [66 (41%) patients] would have been included 
in the remission group. Of these 66 patients, 15 (23%) had tender and six (9%) 
swollen joints, and four (6%) had both tender and swollen joints (66 joint count) 
(Table 15)(Study III). 
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Table 15. Cutoff values of DAS28 and number of patients not fulfilling each 
individual ACR remission criterion.  
 
 
 
 
 
 
 
 
1) The cutoff point corresponding to the ACR remission criteria in this study 
(all the five ACR remission must be fulfilled and fatigue excluded) 
2) The generally accepted cutoff point of DAS28 in remission and the cutoff 
point of ACR remission in this study when modified ACR criteria are used 
(four of the five ACR remission criteria must be fulfilled and fatigue 
excluded) 
3) The cutoff point corresponding to the clinical remission criteria defined as 
no tender or swollen joints and normal ESR 
  
1)DAS28 
<2.32 
 
2)DAS28 
<2.6 
 
3)DAS28 
<2.68 
Patients n  57 66 72 
Patients with tender joints n (%) 
28 joint count 
66 joint count 
 
5 (9%) 
11 (19%) 
 
6 (9%) 
15 (23%) 
 
7 (8%) 
17 (24%) 
Patients with swollen joints n (%) 
28 joint count 
66 joint count 
 
4 (7%) 
6 (11%) 
 
5 (8%) 
6 (9%) 
 
5 (7%) 
6 (8%) 
Patients with tender and swollen 
joints n (%) 
28 joint count 
66 joint count 
 
 
2 (4%) 
4 (7%) 
 
 
2 (4%) 
4 (6%) 
 
 
2 (3%) 
4 (6%) 
Patients with elevated ESR n (%) 2 (4%) 3 (5%) 4 (6%) 
Patients with morning stiffness n (%) 23 (40%) 25 (38%) 27 (38%) 
Patients with joint pain n (%) 33 (58%) 38 (58%) 44 (61%) 
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8.3. DAS28 and MOI-RA in early RA  
In the FIN-RACo trial, the mean value of the DAS28 was 2.78 at six 
months.  The relative contribution of the mean values of the component 
variables to the total DAS28 score according to the DAS28 formula was as 
follows: 1) the mean of  (0.56 x √ TJC) was 0.71 while the median TJC was 2 
(range 0-24), 2) the mean of (0.28 x √ SJC) was 0.23 while the median SJC 
was 0 (range 0-20), 3) the mean of [0.70 x ln(ESR)] was 1.56 while the median 
ESR was 10 (range 1-65), and 4) the mean of (0.014 x GH) was 0.28 while the 
median GH was 15 (range 0-77). Thus the sum of 1 to 4 (0.71+0.23+1.56+0.28) 
was 2.78 (total DAS28 score). Therefore, in this patient population ESR had the 
greatest effect on the DAS28 score with 56% of the total DAS28 score, followed 
by TJC (26%), GH (10%), and SJC (8%)(Study IV). 
In the ‘theoretical model’, TJC (28 joint count) shows the greatest 
effect on the total DAS28 score: when TJC rises from zero to 28, DAS28 
increases from zero to 2.94, provided that the other components remain at zero 
(ESR 1). Accordingly, ESR has the second largest effect on DAS28: when ESR 
rises from zero to 20, DAS28 goes from zero to 2.1. Further, when ESR rises to 
100 DAS28 increases to 3.22. ESR exceeds the effects of all the other 
components when its value is above 70. SJC has the third most powerful effect 
on DAS28 followed by GH, the similarly calculated values of DAS28 being 1.5 
and 1.42, respectively (Figure 7)(Study IV). 
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Figure 7. Effect of each component of DAS28 in the ‘theoretical model’: tender 
joint count, swollen joint count, erythrocyte sedimentation rate (ESR), and 
patient’s general health on DAS28 presuming that the remaining three 
components are at zero (ESR 1). 
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Of the 169 FIN-RACo patients, 107 (63%) had DAS28≤ 3.2 (low 
disease activity), 51 (30%) had DAS28 >3.2 and ≤5.1 (moderate disease 
activity), and 11 (7%) had DAS28 >5.1 (high disease activity) at six months. In 
the high disease activity group the lowest SJC on a 66 joint count was 1 while 
the highest SJC in the low disease activity group was 11. In the low disease 
activity group 42 patients and in the moderate and high disease activity groups 
43 and seven patients, respectively, had a SJC from 1 to 11. In the whole 
patient population, 92 of the 169 patients had a SJC between those limits, so 
the overlapping rate was 92/169 (54%). The similarly calculated overlapping 
rates regarding GH, TJC (68 joint count) and ESR were 49%, 45% and 31%, 
respectively (Figure 8 and Figure 9)(Study IV). 
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Figure 8.  Overlapping in the number of swollen and tender joints on a 66/68 joint count in RA 
patients with low (DAS28≤ 3.2), moderate (DAS28> 3.2 and DAS28≤ 5.1) and high disease 
activity (DAS28> 5.1) according to DAS28. Each circle represents one patient of the FIN-RACo 
trial.   
 
Figure 9.  Overlapping in the erythrocyte sedimentation rate and patient’s general health in RA 
patients with low (DAS28≤ 3.2), moderate (DAS28> 3.2 and ≤ 5.1) and high disease activity 
(DAS28> 5.1) according to DAS28. Each circle represents one patient of the FIN-RACo trial.   
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MOI-RA was examined in the FIN-RACo study. The mean MOI-
RA28 decreased from 38.5 to 13.3 from baseline to six months, compared to a 
decrease of DAS28 from 5.55 to 2.77.   Descriptive statistics and the internal 
consistency of MOI-RA are presented in Table 17. Coefficients of variation were 
higher in MOI-RA than DAS28.  Assumptions of normal distribution were 
satisfied: DAS28 (p= 0.81), MOI-RA28 (p=0.71), MOI-RA42 (p= 0.64) and MOI-
RA66/68 (p=0.66). The reproducibility between MOI-RA indices with different 
joint counts was 0.97 (95%CI 0.88 to 0.99)(Study V).  
  
93
 
T
ab
le
 1
7.
 D
is
tr
ib
ut
io
ns
 a
nd
 in
te
rn
al
 c
on
si
st
en
cy
 o
f M
O
I-R
A
 a
nd
 D
A
S
28
 a
t b
as
el
in
e 
   ×  
(S
D
 o
f t
he
 in
de
x 
at
 b
as
el
in
e/
 m
ea
n 
va
lu
e 
of
 th
e 
in
de
x 
at
 b
as
el
in
e)
 ×
 1
00
. ŧ
 C
on
fid
en
ce
 in
te
rv
al
 o
bt
ai
ne
d 
fr
om
 b
ia
s 
co
rr
ec
te
d 
bo
ot
st
ra
pp
in
g 
(5
00
0 
re
pl
ic
at
io
ns
).
 ŧ 
In
te
rn
al
 c
on
si
st
en
cy
 b
et
w
ee
n 
co
m
po
ne
nt
s 
of
 M
O
I-R
A
 w
as
 e
st
im
at
ed
 b
y 
ca
lc
ul
at
in
g 
C
ro
nb
ac
h’
s 
al
ph
a.
  
D
A
S
2
8
 
M
O
I-
R
A
2
8
 
M
O
I-
R
A
4
2
 
M
O
I-
R
A
6
6
/6
8
 
M
ea
n 
(S
D
) 
5.
55
 (0
.9
8)
 
38
.5
 (1
3.
6)
 
39
.2
 (1
3.
3)
 
35
.6
 (
12
.8
) 
M
ed
ia
n 
(I
Q
R
) 
5.
53
 (4
.9
0,
 6
.1
7)
 
38
.8
 (2
8.
7,
 4
6.
8)
 
38
.6
 (2
8.
3,
 4
7.
1)
 
35
.5
 2
6.
5,
 4
2.
7)
 
R
an
ge
 
3.
03
-8
.0
3 
13
.2
-7
3.
3 
16
.1
-7
2.
2 
13
.8
-7
1.
6 
C
oe
ffi
ci
en
t o
f v
ar
ia
tio
n×
, %
 (9
5%
C
I)
ŧ   
 
18
 (
16
 to
 2
0)
 
35
 (
32
 to
 3
9)
 
34
 (
31
 to
 3
7)
 
36
 (
32
 to
 3
9)
 
S
ke
w
ne
ss
 (
95
%
 C
I) 
  
0.
12
 (-
0.
17
 to
 0
.3
7)
 
0.
40
 (0
.1
8 
to
 0
.6
4)
 
0.
41
 (0
.2
1 
to
 0
.6
7)
 
0.
45
 (0
.2
3 
to
 0
.6
9)
 
K
ur
to
si
s 
(9
5%
 C
I) 
  
2.
9 
(2
.5
-3
.4
) 
2.
8 
(2
.4
 to
 3
.4
) 
2.
7 
(2
.3
 to
 3
.2
) 
2.
8 
(2
.4
 to
 3
.4
) 
In
te
rn
al
 c
on
si
st
en
cy
ŧ  (
95
%
 C
I) 
  
0.
49
 (0
.3
7 
to
 0
.5
9)
 
0.
78
 (0
.7
2 
to
 0
.8
2)
 
0.
80
 (0
.7
5 
to
 0
.8
4)
 
0.
80
 (0
.7
5 
to
 0
.8
4)
 
  
94 
Figure 10 illustrates the mean baseline adjusted change in MOI-RA 
from baseline to six months in patients who did not meet the ACR20, who met 
ACR20 but not ACR50, who met ACR50 but not remission, and who met ACR 
remission criteria. When compared to the ACR response categories (20/50), 
changes in MOI-RA versions (using 28/42/66 joints) were similar (Figure 10). 
The correlation between MOI-RA and DAS28 was between 0.84 and 0.90 
(Table 18)(Study V). 
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Figure 10. Changes in MOI-RA (28, 42 and 66/68 joint counts) in patients who 
did not meet the ACR 20 response, who met the ACR20 but not ACR50, who 
met ACR50 but not remission, and in patients who met remission criteria. 
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Table 18. Correlation× between MOI-RA (with joint counts 28, 42 and 66/68) 
and DAS28 
 
 
× Correlation was calculated with Pearson’s coefficient 
 
The mean MOI-RA (SD) values at baseline with 28, 42 and 66/68 
joint counts were 38.5 (13.6), 39.2 (13.3), and 35.6 (12.8), respectively, 
indicating a decrease in the MOI-RA values from baseline to six months of 
approximately 65%. The mean DAS28 (SD) at baseline was 5.55 (0.98), and a 
50% decrease during the same time period was seen (Table 19).  The 
sensitivity to change of MOI-RA and DAS28 is shown in Figure 11; both indices 
discriminate the two treatment arms significantly. The SRM and ES of both 
DAS28 and MOI-RA for all joint counts were excellent (Table 19)(Study V).  
 DAS28 (95%CI) MOI-RA 28 
(95%CI) 
MOI-RA 
44(95%CI) 
MOI-RA 28 0.90 (0.86 to 0.92)   
MOI-RA 42 0.86 (0.82 to 0.89) 0.99 (0.97 to 1.00)  
MOI-RA 66/68 0.84 (0.79 to 0.87) 0.98 (0.97 to 0.99) 0.99 (0.97 to 1.00) 
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Table 19. Responsiveness of MOI-RA and DAS28 
 
 
 
 
 
SRM= standardized response mean, ES= effect size 
× Confidence interval obtained by bias corrected bootstrapping (5000 
replications)  
 
 
Index Change from baseline 
to six months mean 
(95%CI) 
Change from 
baseline to 
six months % 
SRM× ES× 
DAS28 -2.78 (-2.88 to 2.57) 50% 2.0 (1.8 to 2.3) 2.8 (2.5 to 3.2) 
MOI-RA28 -25.2 (-27.3 to -23.1) 65% 1.8 (1.6 to 2.1) 1.9 (1.6 to 2.1) 
MOI-RA42 -25.4 (-27.4 to -23.4) 65% 1.8 (1.7 to 2.1) 1.9 (1.7 to 2.1) 
MOI-RA66/68 -23.1 (-25.0 to -21.2) 64% 1.8 (1.6 to 2.1) 1.8 (1.6 to 2.0) 
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Figure 11. Decrease of DAS28 and MOI-RA in the monotherapy (SINGLE) and 
combination therapy (COMBI) arm of the FIN-RACo trial from baseline to 12 
months 
 
 
A simulation in which 15% of the component values of MOI-RA 
were randomly omitted (0-3 of the seven measures of one patient could be 
missing) was performed: the ICC was 0.98 (95%CI 0.97 to 0.99) between 
incomplete and complete data (Study V). 
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9. DISCUSSION 
The contemporary approach to treatment of patient with RA  
involves aggressive therapy with DMARDs and biologic agents (Möttönen et al., 
2002; Grigor et al., 2004; Goekoop-Ruiterman et al., 2005; Sokka et al., 2005). 
The goals of treatment are to prevent structural damage, functional impairment, 
work disability, and premature mortality. According to the current guidelines, 
treatment of RA should be targeted at remission (Emery & Salmon, 1995; 
Möttönen et al., 1999). However, remission remains an ambitious aim, which 
may be achieved infrequently in standard clinical care (Wolfe & Hawley, 1985; 
Listing et al., 2006; Mancarella et al., 2007).  In previous studies ACR remission 
rates in clinical RA cohorts range from 0% to 32% (Suarez-Almazor et al., 1994; 
Möttönen et al., 1996; Eberhardt & Fex, 1998; Young et al., 2000; Lindqvist et 
al., 2002; Khanna et al., 2007) and in randomized clinical trials of traditional 
DMARDs from 7% to 37% (Wolfe & Hawley, 1985; Möttönen et al., 1999; 
Ferraccioli et al., 2002; Gerards et al., 2003; Korpela et al., 2004). 
In the present study, rates of remission were studied in a clinical 
cohort using three different definitions of remission: the strict ACR remission 
criteria (fatigue excluded, the other five criteria had to be fulfilled), practical 
clinical remission (no tender joints, no swollen joints, ESR≤ 10mm/h), and 
radiographic remission (no worsening of erosions, no new erosions from 
baseline to five years). Our five-year remission rate of 17% according to the 
ACR criteria lies within the wide range reported in the literature. As expected, 
the rate of clinical remission, which includes three ACR remission criteria but 
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not pain and morning stiffness (or fatigue), was considerably higher compared 
to the ACR remission rate. The high percentage (55%) of patients with no 
radiographic progression over five years was somewhat surprising, but similar 
to results from another cohort in our clinic (Sokka et al., 2004a). 
Wolfe et al. (Wolfe & Hawley, 1985) reported that the sensitivity and 
specificity of the ACR remission criteria were good. Alarcon et al. (Alarcon et al., 
1987) found the criteria to be highly specific but with low sensitivity in some 
patient groups. Nevertheless, fatigue is often excluded when the ACR remission 
criteria are used (Suarez-Almazor et al., 1994; Möttönen et al., 1999; Möttönen 
et al., 2002). In some studies the criteria are considered to be met if all the other 
five items are fulfilled (Suarez-Almazor et al., 1994; Möttönen et al., 1999; 
Möttönen et al., 2002), while in other studies only four of the remaining five 
items are required for remission (Eberhardt & Fex, 1998; Lindqvist et al., 2002).  
Low remission rates are not a surprise since the strict ACR remission criteria 
are not fulfilled by the majority of people aged over 50 in the general population 
(Sokka et al., 2007c). 
All patients fulfilling our definition of clinical remission (no tender 
joints, no swollen joints, ESR≤ 10 mm/h) also met the MDA definition (Wells et 
al., 2005). The proportions of patients fulfilling this definition in early RF positive 
RA patients treated with traditional DMARDs were as follows: 3%, 2% and 3% 
at six, 12 and 24 months (Khanna et al., 2007). In another study, adalimumab 
was started in active RA patients, and this definition was fulfilled by 13% of 
patients at 12 weeks (Burmester et al., 2007). The proportion of these patients 
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who met the criteria are markedly lower than in our study although differences 
in the patient populations do not allow direct comparisons between the studies.  
One could anticipate that radiographic remission would be the most 
rigorous of all remission criteria, since information from previous decades 
shows that radiographic damage starts early and that progression is most rapid 
during the first years of the disease (Fuchs et al., 1989b; Eberhardt et al., 1990; 
van der Heijde et al., 1995; Fex et al., 1996; Kaarela & Kautiainen, 1997; 
Eberhardt & Fex, 1998; Plant et al., 1998; Hulsmans et al., 2000; Jäntti et al., 
2002; Lindqvist et al., 2003; Sokka et al., 2004b). In the study of Lindqvist et al. 
(Lindqvist et al., 2003), almost all (96%) RA patients had erosions at 10 years. 
In the present study, 42% of the patients remained non-erosive throughout the 
five-year follow-up period.  In two previous early RA cohorts from our clinic, 
67% to 86% of patients had erosions within five years (Sokka et al., 2004b). 
Remission is our goal; however, we should not be satisfied with 
transient remission and sustained remission should remain the ultimate target. 
In the FIN-RACo, patients in sustained remission had less radiographic 
progression over two years compared to patients who were in remission at six 
months and lost it later. Less than 50% of our clinical cohort patients who were 
in clinical remission at two years were also in remission at five years. Molenaar 
et al. (Molenaar et al., 2004) followed RA patients in remission for two years. 
Remission persisted in 52% of the patients after two years. The sustainability of 
DAS and DAS28 remissions was also studied in the TEMPO trial comparing the 
efficacy of the combination of MTX and etanercept to the efficacy of these drugs 
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as monotherapies in patients with advanced RA. Remission was assessed 
frequently over one year.  Patients who were treated with  the combination 
therapy managed better than patients who were treated with either of the 
monotherapies with respect to the number and durability of remission periods 
(van der Heijde et al., 2005). Accordingly, our analysis of the FIN-RACo study 
shows that therapy with a combination of traditional DMARDs in patients with 
clinically active early RA leads to sustained remission more often than DMARD 
monotherapy. Furthermore, results from the RABBIT (German biologics 
register) show that biological drugs seem to be superior to conventional 
DMARDs concerning remissions. The overall success rates, however, remain 
low and relapses common. Sustained remission rates of 7.7% for DAS28 
remission and 4.5% for ACR remission were found in patients receiving 
biologics during the follow up time of 12 months (Listing et al., 2006) .  
There is a shift towards less stringent remission criteria, especially 
in RA RCTs.  DAS28 (DAS28< 2.6) remission with higher remission rates has 
replaced the more strict ACR remission criteria in RCTs investigating the 
efficacy of biologic agents (Mäkinen et al., 2006). In the present study 
DAS28<2.32 corresponded to the fulfillment of the modified ACR remission 
criteria and DAS28<2.68 corresponded to the clinical remission criteria (no 
tender or swollen joints and normal ESR). We also calculated the cutoff point of 
DAS28 using a less rigorous set of ACR remission criteria than in previous 
studies (Balsa et al., 2004; Fransen et al., 2004) and the cutoff point was 2.6 in 
agreement with the study of Fransen et al. (Fransen et al., 2004). Even a higher 
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cutoff point of DAS28 2.81  for  this set of ACR remission criteria was reported 
by Balsa et al.(Balsa et al., 2004). DAS28-CRP remission was not examined in 
this study, and even though DAS28-CRP and DAS28-ESR are well correlated, 
the threshold values for remission should be reconsidered (Inoue et al., 2007; 
Matsui et al., 2007a). A DAS28-CRP remission cut-off point of 2.6 has been 
used in one abatacept study(Genovese et al., 2008)  . 
The preliminary RA remission criteria by Pinals et al.(Pinals et al., 
1981) require that five of the six criteria have to be fulfilled. The criteria explicitly 
accept that patients with either tender or swollen joints can be considered to be 
in remission, although not if both tender and swollen joints are present. In our 
study 6% of the patients who were in DAS28 remission (DAS28<2.6) had both 
tender and swollen joints. In another study, a cutoff point of 2.4 allowed the 
presence of up to 12 swollen joints (Aletaha et al., 2005b).   
It appears that remission and sustained remission can be best 
achieved by tight disease control, which is facilitated by using disease activity 
indices. In the TICORA (Tight Control for Rheumatoid Arthritis) (Grigor et al., 
2004) study the target of intensive therapy was to achieve DAS<2.4. The 
intensive strategy was markedly more beneficial than ‘routine care’ with regard 
to disease activity, radiographic progression, physical function, and quality of 
life. At 18 months, 65% of patients in the intensive care group were in DAS 
remission vs. 16% in the routine care group.  The BeSt study (Goekoop-
Ruiterman et al., 2005) compared four treatment strategies in early RA: 
sequential monotherapy, step up combination therapy, and initial combination 
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therapy with either high dose prednisone or infliximab. Treatment was required 
to be intensified if DAS exceeded 2.4. After one year, patients in the initial 
combination therapy had better functional improvement and less radiographic 
joint damage (Goekoop-Ruiterman et al., 2005) compared to the other groups. 
In the CAMERA study, (Computer Assisted Management in Early Rheumatoid 
Arthritis) (Verstappen et al., 2007) intensive and conventional monitoring 
strategies were compared in early RA patients. In the tight control group 
treatment decisions were based on a computer decision program. Remission 
was defined as no swollen joints and two out of three of the following variables: 
number of tender joints ≤ 3, ESR ≤ 20 mm/h, and VAS general wellbeing ≤ 20 
mm. After two years, 50% of the patients in the intensive group versus 37% in 
the conventional group had been in remission for at least six months during the 
study.   Dougados et al.  (Dougados et al., 2007) suggest that low disease 
activity, intensive monitoring, and rapid adjustments in treatment offer the best 
benefit for RA patients.   
Composite scores of disease activity such as DAS28 are of great 
value in RA clinical trials for evaluating the treatment response. However, 
measures with a good discriminatory power in groups of patients may not be 
optimal in individual patients. In our study a substantial proportion of the 
patients with low, moderate and high disease activity defined by DAS28 had 
overlapping values with the other disease activity groups with respect to all four 
disease activity components (TJC, SJC, GH, and ESR). 
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The Ritchie index has a major impact on the original DAS score, 
followed by SJC, ESR and GH (van der Heijde et al., 1993).  Similarly, we found 
in the theoretical model that TJC had the highest impact on DAS28, followed by 
ESR, SJC, and GH. The finding that GH had only a minor impact on the DAS28 
score is not compatible with the fact that GH closely correlates with pain, and 
pain has a substantial impact on the quality of life and function of patients with 
RA (Sokka et al., 2000a; Mäntyselkä et al., 2003).   In the present patient 
population, ESR showed the most powerful impact on DAS28 at six months, 
although the median ESR was only 10.  
The use of biologic agents in many countries has been restricted 
only to patients with high disease activity according to DAS28 (Hjardem et al., 
2005; Ledingham & Deighton, 2005; Gear, 2007). However, the categorical 
application of DAS28 in clinical decision making may be unfeasible and 
inappropriate, as best illustrated by real life patients. One patient in our cohort 
had 21/11 tender (68 joint count/ 28 joint count) and 12/11 swollen (66 joint 
count/ 28 joint count) joints, ESR of 5 and GH of 60. Her DAS28 score of 4.76 
indicated only moderate disease activity.  Another patient had 4/1 tender (68 
joint count/28 joint count) and 11/8 swollen joints (68 joint count/ 28 joint count), 
ESR of 5 and GH of 4 with a DAS28 score of 2.54, indicating DAS28 remission. 
It might be desirable that in addition to DAS28, patient function and potential 
radiographic joint damage (van der Heijde, 2000) are routinely be taken into 
account in adjusting therapies for RA. I agree with the statement of Wolfe et al. 
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(Wolfe et al., 2005b) that DAS28 may not be suitable as the sole criterion for 
initiation and evaluation of therapy with biologics in a clinical setting. 
Although many indices for the assessment of disease activity in RA 
are available, measurement tools with the precision and accuracy of those 
available in other specialties, such as cardiology, do not exist in rheumatology 
(Harth & Pope, 2004). Our purpose when designing MOI-RA was to create an 
index with the highest possible accuracy, by capturing all the important domains 
of disease activity in RA. MOI-RA is a continuous index that enables the 
assessment of current disease activity and can therefore be used in cross 
sectional studies. By definition, MOI-RA can recognize worsening in clinical 
status. Furthermore, in the calculation of MOI-RA no complex mathematical 
functions are needed, and it is easy to understand and calculate. 
MOI-RA results were similar regardless of which joint count (28, 42 
and 66/68) was used.  In other indices, joint counts are fixed. In DAS28 (Prevoo 
et al., 1995) and SDAI (Smolen et al., 2003), 28 joint counts are used and in the 
DAS score, a 44-joint count is applied (van der Heijde et al., 1993; Smolen et 
al., 2003). In DAS, the tender joint count is replaced by the Ritchie articular 
index (Ritchie et al., 1968).  
Clinical RA studies require efforts to collect complete data from 
patients. It is not rare for some data to be missing. If values of patients' general 
health, for example, are missing, DAS28 cannot be calculated and these 
patients have to be omitted from the analyses.  The high imputation stability of 
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MOI-RA provides an opportunity to include patients with incomplete data in 
analyses.  
Two different patient populations were chosen for this study of 
disease activity and remission in RA: patients from an RCT comparing two 
different treatment strategies and patients from a clinical cohort. Disease activity 
indices and remission needed to be tested in both circumstances; in the first 
case, the RA patients included were selected according to inclusion criteria for 
high disease activity, while the latter cohort included all RA patients diagnosed 
in a rheumatology clinic.  
The results of the present study indicate that the rate of remission 
in RA depends on the criteria used. We also showed that sustained remission, 
which is more often achieved by patients receiving combination therapy, 
protects RA patients against radiographic joint damage. Furthermore, although 
the widely used definition of remission, DAS28 remission, is less stringent than 
ACR remission, a substantial proportion of patients below the DAS28 cutoff 
point for remission had tender and/or swollen joints. Finally, I remain somewhat 
skeptical about the notion of a perfect disease activity index in RA. Indices may 
work properly at a group level, but may fail to do so in individual patients due to 
factors that are not associated with inflammation (Leeb et al., 2004), such as 
gender (Leeb et al., 2007).   The MOI-RA index represents an attempt to 
develop an instrument for measuring overall disease activity in RA.  
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10. SUMMARY AND PROSPECTS 
 
 
A modern approach to the treatment of RA includes tight control of 
the disease. This is made possible by frequent follow up visits, systematic 
assessment of disease activity and modification of therapy accordingly (Fransen 
et al., 2005). The target of therapy is a sustained state of remission or minimal 
disease activity, which can be achieved by combining traditional DMARDs or 
methotrexate and biologics (van der Heijde et al., 2005). However, no single 
measure of disease activity and remission in RA exists; various methods have 
been reported and are in use. 
In the present study two different patient cohorts were evaluated: 
patients from a clinical cohort and patients from a RCT. Clinical data were 
analyzed in a cohort including all RA patients diagnosed in 1997-1998 at 
Jyväskylä Central Hospital, and the clinical trial data were acquired from early 
RA patients in the FIN-RACo trial (Möttönen et al., 1999) comparing two 
different treatment strategies. 
We showed that frequency of remission depends on the definition 
used. Further, sustained remission can be achieved with a combination of 
traditional DMARDs. Moreover, sustained remission protects against 
radiographic progression. On the other hand, patients who are in remission 
according to the widely used DAS28< 2.6 remission may still have residual 
disease activity. Although DAS28 has proven to work well at group level, there 
are individual patients whose disease activity may be high despite a DAS28 
value indicating low disease activity. Finally, we developed a new disease 
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activity index for use in RCTs and clinical settings, the Mean Overall Index of 
disease activity (MOI-RA), which captures most dimensions reflecting disease 
activity of RA. 
Patients in the clinical cohort and in the FIN-RACo trial were treated 
actively with traditional DMARDs. This probably contributed to the good 
outcomes - progressive joint destruction was rare. However, the global picture 
of outcomes of RA patients is modest (Sokka et al., 2007b) . In the future, 
effective therapy (with traditional DMARDs in the first place) should be made 
available and given to all RA patients worldwide. 
New information technology will facilitate the follow-up of RA 
patients, including the collection of patient information. A new technology has 
been implemented in data collection in our rheumatology clinic. RA patients 
complete self-report questionnaires using a touch screen with immediate 
storage in a database. This decreases possible data entry mistakes, and the 
data are readily available for the treating health professionals. Diagrams of 
patient’s disease activity and treatments can be produced. In the future, most of 
the data collection may be completed by the patient and a trained nurse instead 
of a physician.  
In conclusion, rheumatologists world wide should become aware 
that benefits for the patient can be obtained by combining the optimal treatment 
strategy with the most appropriate outcome measures. Low disease activity, 
intensive monitoring, and rapid adjustments of treatment appear to promise the 
greatest benefit for the RA patient (Dougados et al., 2007).  
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